Chromium phosphinylhydroisoindole amidine complexes for the tetramerization of ethylene.
A catalyst system using a bicyclic 2-[(phosphinyl)aminyl]cyclic imine and chromium salt complex with an organoaluminum compound enhances the production of alpha olefins from ethylene oligomerization, meeting the growing demand for these chemicals.
Patent Information
- Application Number
- JP2024526963
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-08
- Filing Date
- 2022-11-08
- Publication Date
- 2024-11-08
AI Technical Summary
There is a need for new and improved catalyst systems and methods for the oligomerization of ethylene to produce alpha olefins, as the demand for these chemicals continues to grow and competition for their supply has intensified.
A catalyst system comprising a bicyclic 2-[(phosphinyl)aminyl]cyclic imine and a chromium salt or a bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex is used in the oligomerization of ethylene, in conjunction with an organoaluminum compound, to form oligomeric products.
The catalyst system effectively produces alpha olefins, such as 1-hexene and 1-octene, with improved efficiency and selectivity, addressing the demand for these chemicals.
Smart Images

Figure 2024541296000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure relates to a catalyst system comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine and a chromium salt or a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex. The present disclosure also relates to the use of a catalyst system comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine and a chromium salt or a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex in the oligomerization of ethylene. [Background technology]
[0002] Olefins, also commonly known as alkenes, are important commercial products. Their many uses include as intermediates in the manufacture of surfactants, as precursors to more environmentally friendly refined oils, as monomers, and as precursors to many other types of products. An important subset of olefins are alpha-olefins. One method for the preparation of alpha-olefins is through the oligomerization of ethylene, which is a catalytic reaction involving various types of catalysts and / or catalyst systems. Examples of catalysts and catalyst systems used commercially in the oligomerization of ethylene include selective 1-hexene catalyst systems that include alkylaluminum compounds, certain nickel-phosphine complexes, titanium halides in conjunction with Lewis acids (e.g., diethylaluminum chloride), chromium-containing compounds (e.g., chromium carboxylates), nitrogen-containing ligands (e.g., pyrroles), metal alkyls (e.g., alkylaluminum compounds), and selective trimerization and / or tetramerization catalyst systems that use metal complexes of compounds with diphosphinylaminyl groups.
[0003] Some non-commercial ethylene oligomerization catalyst systems are based on metal complexes of pyridine bis-imines and α-diimine compounds bearing metal complexing groups. These catalyst systems typically use alkylaluminum compounds (e.g., aluminoxanes) to activate the metal complexes for olefin oligomerization.
[0004] As uses and demand for olefins (e.g., alpha olefins) continue to expand and competition for their supply correspondingly intensifies, additional new and improved catalyst systems and processes for ethylene oligomerization are desirable. Summary of the Invention
[0005] i) (a) Structure BPACICr I or Structure BPACICr II [ka] Bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complexes having the formula or (b) a chromium salt and structure BPACI I or structure BPACI II. [ka] and a bicyclic 2-[(phosphinyl)aminyl]cyclic imine having the formula In the formula, R 21 , R 22 , R 23 , and R 24 are independently hydrogen or C1-C 30 may be an organyl group, L 1 , L 2 , and L 3 However, independently, C1~C 30 may be a hydrocarbylene group, R 4 and R 5 However, independently, C1~C 30 R may be an organyl group. 4 and R 5 optionally taken together to form a ring or ring system containing a phosphorus atom, L 45 and L 45 C1~C 30 may be an organylene group, CrX pDisclosed herein is a catalyst system comprising a bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex or a chromium salt and a bicyclic 2-[(phosphinyl)aminyl]cyclic imine, wherein: X is a chromium salt, X is a monoanion, and p is an integer from 2 to 6; and ii) an organoaluminum compound.
[0006] a) i) ethylene and ii) (a)(i) structure BPACICr I and / or structure BPACICr II [ka] 2-[(phosphinyl)aminyl]cyclic imine chromium salt complexes having the formula or (ii) a chromium salt and a compound of structure BPACI I or structure BPACI II. [ka] and a bicyclic 2-[(phosphinyl)aminyl]cyclic imine having the formula In the formula, R 21 , R 22 , R 23 , and R 24 are independently hydrogen or C1-C 30 may be an organyl group, L 1 , L 2 , and L 3 However, independently, C1~C 30 may be a hydrocarbylene group, R 4 and R 5 However, independently, C1~C 30 R may be an organyl group. 4 and R 5 optionally taken together to form a ring or ring system containing a phosphorus atom, L 45 and L 45 C1~C 30 may be an organylene group, CrX pAlso disclosed herein is a process comprising: contacting a catalyst system comprising a 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex or a chromium salt and a bicyclic 2-[(phosphinyl)aminyl]cyclic imine, where X is a chromium salt, X is a monoanion, and p is an integer from 2 to 6; (b) an organoaluminum compound; and, optionally, an organic reaction medium; and b) forming an oligomeric product in a reaction zone. [Brief description of the drawings]
[0007] [Figure 1] Plot of the calculated Gibbs free energy difference ΔΔG‡ between the transition states yielding 1-hexene and 1-octene versus the natural logarithm (ln(C6 / C8)) of the amounts of 1-hexene and 1-octene for five ethylene oligomerizations experimentally evaluated using five N2-phosphinyl amidine chromium salt complex catalyst systems and predicted values of ΔΔG‡. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] The following definitions are provided to more clearly define the terms used herein. Unless otherwise specified, the following definitions are applicable to this disclosure. If a term is used in this disclosure but is not specifically defined herein, the definition in the IUPAC Compendium of Chemical Terminology, 2nd Ed (1997) may be applied, unless the definition conflicts with any other disclosure or definition applied herein, or obscures or disables any claim to which the definition applies. To the extent that any definition or usage provided by any document incorporated by reference herein conflicts with the definition or usage provided herein, the definition or usage provided herein shall take precedence.
[0009] Groups of elements in the periodic table are designated using the numbering scheme set forth in the Periodic Table of the Elements, version published in Chemical and Engineering News, 63(5), 27, 1985. In some cases, groups of elements may be designated using the common name assigned to that group: for example, alkaline earth metals (or alkali metals) for Group 1 elements, alkaline earth metals (or alkali metals) for Group 2 elements, transition metals for Groups 3-12 elements, and halogens for Group 17 elements.
[0010] With respect to transitional terms or phrases in a claim, the transitional term "comprising" (which is synonymous with "including," "containing," "having," or "characterized by") is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. The transitional phrase "consisting of" excludes any element, step, or ingredient not specified in the claim. The transitional phrase "consisting essentially of" limits the scope of the claim to certain materials or steps and those that do not materially affect the basic and novel characteristic(s) of the subject matter described herein. A "consisting essentially of" claim occupies an intermediate position between a closed claim written in a "consisting of" format and a fully open-ended claim drafted in a "comprising" format. Unless otherwise specified, when describing a compound or composition, "consisting essentially of" should not be construed as "comprising," but is intended to describe the described components, including materials that do not significantly change the composition or method to which the term is applied. For example, a feedstock consisting essentially of material A may include impurities that are typically present in commercially produced or commercially available samples of the described compound or composition. When a claim includes different features and / or feature classes (e.g., process steps, feedstock features, and / or product features, among other possibilities), the transitional terms "comprising," "consisting essentially of," and "consisting of" apply only to the feature class that is utilized, and different transitional terms or phrases may be utilized for different features within the claim.For example, a method may include some recited steps (and other non-recited steps), but utilizes a catalyst system preparation consisting of the specified steps, or alternatively, may utilize a catalyst system consisting of the specified steps and / or including the recited components and other non-recited components.
[0011] The use of "comprising" or an equivalent expression herein contemplates the use of the phrases "consisting essentially of," "consists essentially of," or equivalent expressions as alternative embodiments to this open-ended expression. Additionally, the use of "comprising" or an equivalent expression or the use of "consisting essentially of" herein contemplates the use of the phrases "consisting of," "consists of," or equivalent expressions, respectively, as alternative embodiments to this open-ended or intermediate expression. For example, "comprising" should be understood to include "consisting essentially of" and "consisting of" as alternative embodiments of the aspects, features, and / or elements set forth herein, unless specifically specified otherwise.
[0012] While compositions and methods are described in terms of "comprising" various components or steps, the compositions and methods can also "consist essentially of" or "consist of" various components or steps.
[0013] The terms "a," "an," and "the" are intended to include multiple alternatives (e.g., at least one) unless specifically specified otherwise. For example, a disclosure of "a trialkylaluminum compound" is intended to encompass one trialkylaluminum compound, or a mixture or combination of multiple trialkylaluminum compounds, unless otherwise specified.
[0014] For any particular compound disclosed herein, unless otherwise specified, the general structure or name shown is intended to encompass all structural isomers, conformational isomers, and stereoisomers that may result from a particular set of substituents. Thus, a general reference to a compound includes all structural isomers unless otherwise specifically specified, for example, a general reference to pentane includes n-pentane, 2-methyl-butane, and 2,2-dimethylpropane, while a general reference to a butyl group includes n-butyl, sec-butyl, iso-butyl, and tert-butyl. Furthermore, a reference to a general structure or name, where the context permits or where appropriate, includes all enantiomers, diastereomers, and other optical isomers, whether in enantiomeric or racemic form, as well as mixtures of stereoisomers. For any particular formula or name shown, any general formula or name shown also encompasses all conformational isomers, positional isomers, and stereoisomers that may result from a particular set of substituents.
[0015] Chemical "groups" are described according to how they are formally derived from a reference or "parent" compound, for example, by the number of hydrogen atoms formally removed from the parent compound to produce the group, even if the group was not literally synthesized in this manner. Such groups may be utilized as substituents or coordinated or bonded to metal atoms. As an example, an "alkyl group" may be formally obtained by removing one hydrogen atom from an alkane, while an "alkylene group" may be formally obtained by removing two hydrogen atoms from an alkane. Furthermore, a more general term may be used to encompass a variety of groups that are formally obtained by removing any number ("one or more") of hydrogen atoms from a parent compound, and in this example, the more general term may be described as an "alkane group," which encompasses "alkyl groups," "alkylene groups," and substances in which three or more hydrogen atoms have been removed from an alkane, depending on the context. Throughout, disclosures that substituents, ligands, or other chemical moieties may constitute a particular "group" imply that well-known chemical structure and bonding rules are observed when that group is used as described. When groups are described as being "obtained by," "obtained from," "formed by," or "formed from," such terms are used in a formal sense and are not intended to reflect any particular synthetic method or procedure, unless otherwise specified or the context requires otherwise.
[0016] The term "substituted," when used to describe a group, for example when referring to a substituted analog of a particular group, is intended to describe any non-hydrogen moiety that formally replaces a hydrogen in the group and is intended to be open-ended. A group(s) may also be referred to herein as "unsubstituted" or by equivalent terms such as "non-substituted," which refers to the original group in which a hydrogen in the group is not replaced by a non-hydrogen moiety. "Substituted" is intended to be open-ended and include both inorganic and organic substituents.
[0017] Bicyclic 2-[(phosphinyl)aminyl]cyclic imine refers to a compound having a bicyclic imine having a (phosphinyl)aminyl group attached to a carbon atom of the imine group. Bicyclic imine refers to an imine contained within a bicyclic structure.
[0018] The term "organyl group" is used herein according to the definition provided by IUPAC: an organic substituent having one free valence at a carbon atom, regardless of its functional type. Similarly, an "organylene group" refers to an organic group, regardless of its functional type, obtained by removing two hydrogen atoms from an organic compound, i.e., either removing two hydrogen atoms from one carbon atom or removing one hydrogen atom from each of two different carbon atoms. An "organic group" refers to a generalized group formed by removing one or more hydrogen atoms from a carbon atom of an organic compound. Thus, an "organyl group", "organylene group", and "organic group" may contain organic functional group(s) and / or atom(s) other than carbon and hydrogen, i.e., an organic group may contain functional groups and / or atoms in addition to carbon and hydrogen. An "organyl group", "organylene group", and "organic group" may be aliphatic (including those that are cyclic or acyclic or straight-chained or branched) or aromatic.
[0019] For the purposes of this application, the term "organyl group consisting of inert functional groups" or variations of this term refers to organyl groups in which the organic functional group(s) and / or atom(s) other than carbon and hydrogen present in the functional group(s) are limited to those functional groups and / or atom(s) other than carbon and hydrogen that do not complex with metal compounds under the process conditions defined herein and / or are inert. Thus, the term "organyl group consisting of inert functional groups" or variations of this term further defines the specific organyl groups that may be present within the organyl group consisting of inert functional groups. Furthermore, the term "organyl group consisting of inert functional groups" may refer to the presence of one or more inert functional groups within the organyl group. The term "organyl group consisting of inert functional groups" or variations of this term include hydrocarbyl groups as members (among other groups). Similarly, an "organylene group consisting of an inert functional group" refers to an organic group formed by removing two hydrogen atoms from one or two carbon atoms of an organic compound consisting of an inert functional group, and an "organic group consisting of an inert functional group" refers to a generalized organic group consisting of an inert functional group formed by removing one or more hydrogen atoms from one or more carbon atoms of an organic compound consisting of an inert functional group.
[0020] For purposes of this application, an "inert functional group" is a group that does not substantially interfere with the processes described herein, and a material having an inert functional group is part of a metal complex and / or does not complex with the metal compound of the metal complex. The term "does not complex with the metal compound" may include a group that is capable of complexing with a metal compound, but in certain molecules described herein, is unable to complex with the metal compound due to its positional relationship within the ligand. For example, an ether group may complex with a metal compound, but an N 2 The ether group located at the para position of the substituted phenylphosphinyl group in the -phosphinyl amidine may be an inert functional group, because a single metal compound may have a para-ether group and a N-phosphinyl amidine in the same metal complex molecule. 2-phosphinyl amidine groups. Thus, the inertness of a particular functional group may not only be related to the inherent inability of the functional group to complex with a metal compound, but also to the location of the functional group within the metal complex. Non-limiting examples of inert functional groups that do not substantially interfere with the processes described herein may include, among others, halo (fluoro, chloro, bromo, and iodo), nitro, hydrocarboxy groups (e.g., alkoxy and / or aroxy), sulfidyl groups, and / or hydrocarbyl groups.
[0021] The term "hydrocarbon" whenever used in the specification and claims refers to a compound containing only carbon and hydrogen. Other identifiers may be utilized to indicate the presence of a particular group in the hydrocarbon (e.g., halogenated hydrocarbon indicates the presence of one or more halogen atoms in the hydrocarbon replacing an equal number of hydrogen atoms). The term "hydrocarbyl group" is used herein according to the definition provided by IUPAC, a monovalent group formed by removing a hydrogen atom from a hydrocarbon. Similarly, a "hydrocarbylene group" refers to a group formed by removing two hydrogen atoms from a hydrocarbon, i.e., either by removing two hydrogen atoms from one carbon atom or by removing one hydrogen atom from each of two different carbon atoms. Thus, according to the terminology used herein, a "hydrocarbon group" refers to a generalized group formed by removing one or more hydrogen atoms (depending on the needs of the particular group) from a hydrocarbon. "Hydrocarbyl group", "hydrocarbylene group", and "hydrocarbon group" may be acyclic or cyclic groups, and / or may be straight or branched chain. "Hydrocarbyl groups", "hydrocarbylene groups", and "hydrocarbon groups" can include rings, ring systems, aromatic rings, and aromatic ring systems that contain only carbon and hydrogen. "Hydrocarbyl groups", "hydrocarbylene groups", and "hydrocarbon groups" include, for example, aryl, arylene, arene, alkyl, alkylene, alkane, cycloalkyl, cycloalkylene, cycloalkane, aralkyl, aralkylene, and aralkane groups as members, among other groups.
[0022] The term "alkane" whenever used in the specification and claims refers to a saturated hydrocarbon compound. Other identifiers may be utilized to indicate the presence of a particular group in the alkane (e.g., a halogenated alkane indicates the presence of one or more halogen atoms in the alkane replacing an equal number of hydrogen atoms). The term "alkyl group" is used herein according to the definition provided by IUPAC, a monovalent group formed by removing a hydrogen atom from an alkane. Similarly, an "alkylene group" refers to a group formed by removing two hydrogen atoms from an alkane (either two hydrogen atoms from one carbon atom or one hydrogen atom from two different carbon atoms). An "alkane group" is a general term that refers to a group formed by removing one or more hydrogen atoms from an alkane (depending on the needs of the particular group). An "alkyl group", "alkylene group", and "alkane group" may be acyclic or cyclic, and / or straight or branched chain, unless otherwise specified. Primary, secondary, and tertiary alkyl groups are obtained by removing hydrogen atoms from primary, secondary, or tertiary carbon atoms of alkanes, respectively. n-Alkyl groups can be obtained by removing hydrogen atoms from the terminal carbon atoms of straight-chain alkanes.
[0023] Cycloalkanes are saturated cyclic hydrocarbons with or without side chains, for example, cyclobutane. Unsaturated cyclic hydrocarbons with one or more double bonds or one triple bond in the ring are called cycloalkenes and cycloalkynes, respectively. Cycloalkenes and cycloalkynes with only one, two, three, etc. double or triple bonds in the ring, respectively, can be identified by using terms such as "mono", "di", "tri" in the name of the cycloalkene or cycloalkyne. Cycloalkenes and cycloalkynes can be further identified by the position of the double or triple bond in the ring.
[0024] The term "substituted," when used to describe a compound or group, for example when referring to a substituted analog of a particular compound or group, is intended to describe any non-hydrogen moiety that formally replaces a hydrogen in the group and is intended to be open-ended. A group(s) may also be referred to herein as "unsubstituted" or by equivalent terms such as "non-substituted," which refers to the original group in which a hydrogen in the group is not replaced by a non-hydrogen moiety. "Substituted" is intended to be open-ended and include both inorganic and organic substituents.
[0025] The term "olefin" whenever used in the present specification and claims refers to a hydrocarbon having at least one carbon-carbon double bond that is not part of an aromatic ring or aromatic ring system. The term "olefin" includes aliphatic and aromatic, acyclic and cyclic, and / or straight-chain and branched-chain compounds having at least one carbon-carbon double bond that is not part of an aromatic ring or aromatic ring system, unless expressly stated otherwise. Olefins having only one, two, three, etc. carbon-carbon double bonds can be identified by using terms such as "mono", "di", "tri" in the name of the olefin. Olefins can be further identified by the position of the carbon-carbon double bond(s).
[0026] The term "alkene" whenever used in the specification and claims refers to a straight or branched chain hydrocarbon olefin having one or more carbon-carbon double bonds. Alkenes having only one, two, three, etc. such multiple bonds can be identified by using terms such as "mono", "di", "tri" in the name. Alkenes can be further identified by the position of the carbon-carbon double bond(s). Other identifiers can be utilized to indicate the presence or absence of certain groups in the alkene. For example, a haloalkene refers to an alkene in which one or more hydrogen atoms have been replaced with a halogen atom.
[0027] The term "alpha olefin" as used herein and in the claims refers to an olefin having a carbon-carbon double bond between the first and second carbon atoms of the longest continuous chain of carbon atoms. The term "alpha olefin" includes linear and branched alpha olefins unless expressly stated otherwise. In the case of branched alpha olefins, the branch may be located at the 2-position (vinylidene) and / or 3-position or higher relative to the olefinic double bond. The term "vinylidene" whenever used herein and in the claims refers to an alpha olefin having a branch at the 2-position relative to the olefinic double bond. The term "alpha olefin" by itself does not indicate the presence or absence of other carbon-carbon double bonds unless expressly stated otherwise. The term "linear alpha olefin" as used herein refers to an unbranched alpha olefin having a carbon-carbon double bond between the first and second carbon atoms.
[0028] The term "normal alpha olefin" whenever used in this specification and claims refers to a straight chain hydrocarbon mono-olefin having a carbon-carbon double bond between the first and second carbon atoms. It is noted that "normal alpha olefin" is not synonymous with "linear alpha olefin" as the term "linear alpha olefin" can include straight chain olefin compounds having a double bond between the first and second carbon atoms as well as additional double bonds.
[0029] An aliphatic compound is an acyclic or cyclic, saturated or unsaturated carbon compound, excluding aromatic compounds. Thus, an aliphatic compound is an acyclic or cyclic, saturated or unsaturated carbon compound, excluding aromatic compounds, i.e., an aliphatic compound is a non-aromatic organic compound. An "aliphatic group" is a generalized group formed by removing one or more hydrogen atoms (depending on the needs of the particular group) from a carbon atom of an aliphatic compound. An aliphatic compound, and thus an aliphatic group, may contain organic functional group(s) and / or atom(s) other than carbon and hydrogen.
[0030] Aromatic compounds are compounds that contain a cyclic conjugated double bond system containing (4n+2) π electrons (n is an integer between 1 and 5) according to the Hückel (4n+2) rule. Aromatic compounds include "arenes" (hydrocarbon aromatic compounds) and "heteroarenes" (also called "hetarenes"), which are heteroaromatic compounds that are formally derived from arenes by replacing one or more methine (-C=) carbon atoms of the cyclic conjugated double bond system with trivalent or divalent heteroatoms in a manner that maintains the continuous π electron system and some out-of-plane π electrons characteristic of aromatic systems in accordance with the Hückel (4n+2) rule. Arene compounds and heteroarene compounds are mutually exclusive members of the group of aromatic compounds, while compounds that have both arene and heteroarene groups are generally considered heteroarene compounds. Aromatic compounds, arenes, and heteroarenes can be monocyclic (e.g., benzene, toluene, furan, pyridine, methylpyridine) or polycyclic, unless otherwise specified. Polycyclic aromatic compounds, arenes, and heteroarenes, unless otherwise specified, include compounds in which the aromatic rings may be fused (e.g., naphthalene, benzofuran, and indole), aromatic groups may be separated and connected by bonds (e.g., biphenyl or 4-phenylpyridine), or aromatic groups are linked by groups that contain linking atoms (e.g., carbon in the methylene group in diphenylmethane, oxygen in diphenylether, nitrogen in triphenylamine, among other linking groups). As disclosed herein, the term "substituted" may be used to describe an aromatic group, arene, or heteroarene in which hydrogen in the compound is formally replaced by a non-hydrogen moiety and is intended to be non-limiting.
[0031] An "aromatic group" refers to a generalized group formed by removing one or more hydrogen atoms (at least one of which originates from an aromatic ring carbon atom, depending on the needs of the particular group) from an aromatic compound. For a monovalent "aromatic group", the removed hydrogen atom must originate from an aromatic ring carbon. For an "aromatic group" formed by removing multiple hydrogen atoms from an aromatic compound, at least one hydrogen atom must originate from an aromatic hydrocarbon ring carbon. Furthermore, an "aromatic group" may be one in which a hydrogen atom has been removed from the same ring of an aromatic ring or aromatic ring system (e.g., pheno-1,4-ylene, pyridin-2,3-ylene, naphth-1,2-ylene, and benzofuran-2,3-ylene), one in which a hydrogen atom has been removed from two different rings of a ring system (e.g., naphth-1,8-ylene and benzofuran-2,7-ylene), or one in which a hydrogen atom has been removed from two separate aromatic rings or aromatic ring systems (e.g., bis(pheno-4-ylene)methane).
[0032] "Aryl compound" refers to an aromatic hydrocarbon. "Aryl group" refers to a monovalent aromatic hydrocarbon having a free valence at an aromatic ring carbon atom. Similarly, "arylene group" refers to a group derived from an aromatic hydrocarbon by removing two hydrogen atoms, at least one of which originates from an aromatic ring carbon. Thus, "arylene group" includes groups derived from aromatic hydrocarbons in which two hydrogen atoms have been formally removed from the same aromatic ring carbon, groups derived from aromatic hydrocarbons in which two hydrogen atoms have been formally removed from two different aromatic ring carbons, and groups derived from aromatic hydrocarbons in which a first hydrogen atom has been formally removed from an aromatic ring carbon and a second hydrogen atom has been formally removed from a carbon atom that is not an aromatic ring carbon. "Aromatic hydrocarbon group" refers to a generalized group formed by removing one or more hydrogen atoms (at least one of which originates from an aromatic ring carbon, depending on the needs of the particular group) from an aromatic hydrocarbon compound.
[0033] An "arylalkane" refers to an aromatic hydrocarbon having at least one alkyl group substituent. An "aralkyl group" is an aryl-substituted alkyl group having a free valence at a non-aromatic carbon atom of the arylalkane (e.g., benzyl or 2-phenyleth-1yl, among others). Similarly, an "aralkylene group" is an aryl-substituted alkylene group having two free valences at a single non-aromatic carbon atom of the arylalkane, or an aryl-substituted alkylene group having free valences at two non-aromatic carbon atoms of the arylalkane, while an "aralkane group" is an aryl-substituted alkane group having one or more free valences at a non-aromatic carbon atom(s) of the arylalkane. According to the definitions provided herein, typical aralkane groups include those having zero, one, or more hydrocarbyl substituents located at the aralkane aromatic hydrocarbon ring carbon atom or at the aralkane aromatic hydrocarbon ring system carbon atom, and it should be noted that typical aralkane groups are members of the group of hydrocarbon groups. On the other hand, a specific aralkane group that defines a specific aryl group (such as, inter alia, a benzyl group or a phenyl group in a 2-phenylethyl group) refers to a specific unsubstituted aralkane group (not including a hydrocarbyl group located on an aralkane aromatic hydrocarbon ring carbon atom or an aralkane aromatic hydrocarbon ring system carbon atom). As a result, a substituted aralkane group that defines a specific aryl group refers to a respective aralkane group having one or more substituents (including, inter alia, a halogen, a hydrocarbyl group, or a hydrocarboxy group). When a substituted aralkane group that defines a specific aryl group is a member of a group of hydrocarbon groups (or a member of a general group of aralkane groups), each substituent is limited to a hydrocarbyl substituent. It is easily possible to identify and select a substituted aralkane group that defines a specific aryl group that can be used as a member of a group of hydrocarbon groups (or a member of a general group of aralkane groups).
[0034] "Halide" has its ordinary meaning; thus, examples of halides include fluoride, chloride, bromide, and iodide.
[0035] As used herein, the term "reactor" refers to a discrete unit of equipment (e.g., a vessel) in which a reaction occurs, but excludes any associated equipment outside the vessel (such as piping, pumps, and the like). Examples of reactors include stirred tank reactors (e.g., continuous stirred tank reactors), plug flow reactors, or any other type of reactor. As used herein, a "reaction zone" refers to any portion of the equipment in which a desired reaction occurs, including, but not limited to, the reactor, associated piping, associated pumps, and any other associated equipment. It should be noted that in some cases, a "reactor" can also be a "reaction zone." The terms "reactor" and "reaction zone" can be qualified to refer to more specific "reactors" and "reaction zones" by the use of additional qualifying terms. For example, the use of the terms "oligomerization reactor" and "oligomerization reaction zone" indicates that the desired reaction in the reactor and / or reaction zone is an oligomerization reaction.
[0036] As used herein, the term "reaction zone" refers to a portion of a process, associated equipment, and associated process line in which all necessary reactants and reaction conditions are present so that a reaction can occur at a desired rate. That is, a reaction zone begins when the necessary reactants and reaction conditions are present to maintain a reaction within 25 percent of the average reaction rate (based on the volume average of the reaction rate of the reaction system) and ends when the conditions do not maintain a reaction rate within 25 percent of the average reaction rate. For example, with respect to an oligomerization process, a reaction zone begins when there are sufficient feedstocks and an active catalyst system under sufficient reaction conditions to maintain oligomer product production at a desired rate and ends when the catalyst system is deactivated, when there are not enough feedstocks to maintain oligomer product production, or when other reaction conditions are not sufficient to maintain oligomer product production or the desired oligomer product production rate. As used herein, a "reaction zone" can include one or more reactor zones, one or more reactors, and associated equipment in which all necessary reactants and reaction conditions are present so that a reaction can occur at a desired rate. Use of the term "oligomerization reaction zone" indicates that the desired reaction within the reaction zone is an oligomerization reaction.
[0037] The term "room temperature" or "ambient temperature" is used herein to describe any temperature between 15°C and 35°C where no external heat or cooling source is directly applied. Thus, the terms "room temperature" and "ambient temperature" encompass the individual temperatures between 15°C and 35°C where no external heat or cooling source is directly applied, as well as any and all temperature ranges, sub-temperature ranges, and sub-temperature range combinations. The term "atmospheric pressure" is used herein to describe ground air pressure where no external pressure modifying means are utilized. Generally, unless practiced at extreme ground altitudes, "atmospheric pressure" is about 1 atmosphere (alternatively, about 14.7 psi or about 101 kPa). References to gas, liquid, and / or solid substances refer to the physical state of the substance at 25°C and atmospheric pressure, unless otherwise specified.
[0038] Features within the present disclosure provided as minimum values may alternatively be described as "at least" any stated minimum value for the feature disclosed herein or "greater than or equal to" any stated minimum value. Features within the present disclosure provided as maximum values may alternatively be described as "less than or equal to" any feature disclosed herein.
[0039] Within this disclosure, normal organic compound nomenclature rules will be used. For example, when there is a reference to a substituted compound or group, reference is made to the substitution pattern to indicate that the specified group(s) are located at the specified positions, and all other non-specified positions are hydrogen. For example, reference to a 4-substituted phenyl group indicates that there is a non-hydrogen substituent located at the 4 position, as well as hydrogens located at the 2, 3, 5, and 6 positions. As another example, reference to a 3-substituted naphth-2-yl indicates that there is a non-hydrogen substituent located at the 3 position, as well as hydrogens located at the 1, 4, 5, 6, 7, and 8 positions. Reference to a compound or group having substitutions at positions other than the specified positions will be referred to using "comprising" or some other alternative wording. For example, reference to a phenyl group containing a substituent at the 4 position refers to the group having a non-hydrogen atom at the 4 position, and hydrogens or any non-hydrogen groups at the 2, 3, 5, and 6 positions.
[0040] Described herein are processes for forming oligomeric products. Such processes generally include contacting ethylene with a catalyst system (or alternatively, contacting ethylene with components of the catalyst system) under oligomerization conditions to form the oligomeric products.
[0041] The term "reaction zone effluent" and its derivatives (e.g., oligomerization reaction zone effluent, trimerization reaction zone effluent, tetramerization reaction zone effluent, or trimerization and tetramerization reaction zone effluent) generally refers to all materials exiting a reaction zone. Materials that may exit a reaction zone include reaction feed(s) (e.g., ethylene, catalyst system or catalyst system components, and / or organic reaction medium) and / or reaction product(s) (e.g., oligomer product, including oligomers and non-oligomers). The term "reaction zone effluent" and its derivatives may be limited to refer to certain portions by the use of additional limiting terms. For example, reaction zone effluent refers to all materials exiting a reaction zone, while reaction zone oligomer product effluent refers only to the oligomer product in the reaction zone effluent.
[0042] The term "oligomerization" and its derivatives refer to a process that produces a mixture of products that includes at least 70 weight percent of products that contain 2 to 30 ethylene units. Similarly, as used herein, an "oligomer" is a product that contains 2 to 30 ethylene units, while an "oligomerization product" or "oligomer product" includes all products prepared by the process, including "oligomers" and products that are not "oligomers" (e.g., products that contain more than 30 ethylene units). Additionally, the terms "oligomer product" and "oligomerization product" may be used interchangeably.
[0043] The term "trimerization" and its derivatives refer to a process that produces a mixture of products that contains at least 70 weight percent of products that contain exactly three ethylene units. A "trimer" is a product that contains exactly three ethylene units, while a "trimerization product" includes all products prepared by the trimerization process, including trimers and products that are not trimers (e.g., dimers or tetramers). Generally, a "trimerization" process using ethylene produces an oligomeric product that contains at least 70 weight percent hexene(s).
[0044] The term "tetramerization" and its derivatives refer to a process that produces a mixture of products that contains at least 70 weight percent of products that contain exactly four ethylene units. A "tetramer" is a product that contains exactly four ethylene units, while a "tetramerization product" includes all products prepared by a tetramerization process, including tetramers and products that are not tetramers (e.g., dimers or trimers). Generally, a "tetramerization" process using ethylene produces an oligomeric product that contains at least 70 weight percent octene(s).
[0045] The term "trimerization and tetramerization" and its derivatives refer to a process that produces a mixture of products that contains at least 70 weight percent of products that contain exactly three and / or four ethylene units. "Trimerization and tetramerization products" include all products prepared by the "trimerization and tetramerization" process, including trimers, tetramers, and products that are neither trimers nor tetramers (e.g., dimers). Generally, the "trimerization and tetramerization" process using ethylene produces oligomeric products that contain at least 70 weight percent hexene(s) and / or octene(s).
[0046] Unless otherwise specified, the terms "contacted," "integrated," and "in the presence of" refer to any order of addition, sequence, or concentration for contacting or integrating two or more components of a process. Integrating or contacting the components can occur in one or more contact zones under appropriate contact conditions (temperature, pressure, contact time, flow rate, etc.) according to various methods described herein. The contact zone can be located in a vessel (e.g., a storage tank, tote, container, mixing vessel, reactor, etc.), a length of tubing (e.g., a tee, inlet, injection port, or header for integrating component supply lines into a common line), or any other suitable equipment for contacting the components. The process can be carried out in a batch or continuous process as may be suitable for a given embodiment.
[0047] Use of the term "optionally" with respect to any element of a claim is intended to mean that the subject element is required or, alternatively, is not required. Both alternatives are intended to be within the scope of the claim.
[0048] The processes described herein may utilize steps, features, compounds, and / or devices described independently herein. The processes described herein may or may not utilize step identifiers (e.g., 1), 2), etc., a), b), etc., i), ii), etc., or first, second, etc., among others), feature identifiers (e.g., 1), 2), etc., a), b), etc., i), ii), etc., or first, second, etc., among others), and / or compound and / or composition identifiers (e.g., 1), 2), etc., a), b), etc., i), ii), etc., or first, second, etc., among others). However, it is noted that the processes described herein may have multiple steps, features (e.g., reagent ratios, formation conditions, among other considerations), and / or multiple compounds and / or compositions that do not use descriptors or that may have the same general identifier. Consequently, it is noted that the processes described herein may be modified to use appropriate step or feature identifiers (e.g., 1), 2), etc., a), b), etc., i), ii), etc., or first, second, etc.), feature identifiers (e.g., 1), 2), etc., a), b), etc., i), ii), etc., or first, second, etc., and / or compound identifiers (e.g., first, second, etc.), regardless of the step, feature, and / or compound identifiers utilized in a particular embodiment described herein, and that step or feature identifiers may be added and / or modified to indicate the individual different steps / features / compounds utilized within the process without departing from the general disclosure.
[0049] The present disclosure relates to a catalyst system comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex, or alternatively a catalyst system comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine and a chromium salt. In one embodiment, the catalyst system can comprise or consist essentially of a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex and an organoaluminum compound, or alternatively a bicyclic 2-[(phosphinyl)aminyl] cyclic imine, a chromium salt, and an organoaluminum compound. The present disclosure also relates to a process comprising: a) contacting i) ethylene with ii) a catalyst system comprising (a) (i) a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex or (ii) a chromium salt and a bicyclic 2-[(phosphinyl)aminyl] cyclic imine, and (b) an organoaluminum compound, and iii) optionally an organic reaction medium, and b) forming oligomeric products in a reaction zone. The bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex, the chromium salt, the bicyclic 2-[(phosphinyl)aminyl] cyclic imine, the organoaluminum compound, and the optional organic reaction medium that may be utilized in the catalyst system and process are described herein independently and may be utilized in any combination without limitation to describe the catalyst system and process of the present disclosure.
[0050] Generally, the bicyclic 2-[(phosphinyl)aminyl] cyclic imine and bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes encompassed by the present disclosure have at least one bicyclic 2-[(phosphinyl)aminyl] cyclic imine group. In one embodiment, the bicyclic 2-[(phosphinyl)aminyl] cyclic imine and bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes may contain only one bicyclic 2-[(phosphinyl)aminyl] cyclic imine group, or alternatively may contain only two bicyclic 2-[(phosphinyl)aminyl] cyclic imine groups. In one embodiment, the bicyclic 2-[(phosphinyl)aminyl] cyclic imine can be non-metallic (i.e., a non-metallic bicyclic 2-[(phosphinyl)aminyl] cyclic imine or a non-metallic compound having a bicyclic 2-[(phosphinyl)aminyl] cyclic imine group) regardless of the number or structure of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine group. In some embodiments, the bicyclic 2-[(phosphinyl)aminyl] cyclic imine and / or bicyclic 2-[(phosphinyl)aminyl] cyclic imine group of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex can be an acyclic amidine group (an amidine group in which the two nitrogen atoms and the central carbon atom of the amine group are not contained within the same ring).
[0051] In one embodiment, the bicyclic 2-[(phosphinyl)aminyl] cyclic imine can have the structure BPACI I or BPACI II. In one embodiment, the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex can have the structure BPACICr I or BPACICr II. [ka] In the bicyclic 2-[(phosphinyl)aminyl]cyclic imines having the structures BPACI I and / or BPACI II, R 21 , R 22 , R 23 , R 24 , L 1 , L 2 , L 3 , R 4 , and R 5R is an independent element of a bicyclic 2-[(phosphinyl)aminyl]cyclic imine having the structure BPACI I and / or BPACI II, and is described independently herein. 21 , R 22 , R 23 , R 24 , L 1 , L 2 , L 3 , R 4 , and R 5 The independent descriptions of may be utilized in any combination, without limitation, to describe a bicyclic 2-[(phosphinyl)aminyl]cyclic imine having the structure BPACI I and / or BPACI II that may be utilized in any embodiment described herein. In a bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex having the structure BPACICr I and / or BPACICr II, the R of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine is 21 , R 22 , R 23 , R 24 , L 1 , L 2 , L 3 , R 4 , and R 5 , and chromium salts CrX p R is an independent element of a bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex having the structure BPACICr I and / or BPACICr, and is described independently herein. 21 , R 22 , R 23 , R 24 , L 1 , L 2 , L 3 , R 4 , R 5 , and CrX p The independent descriptions may be utilized in any combination, without limitation, to describe bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complexes having the structures BPACICr I and / or BPACICr II that may be utilized in any embodiment described herein.
[0052] Generally, R of a bicyclic 2-[(phosphinyl)aminyl] cyclic imine structure and / or a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex structure 21 , R 22 , R 23 , and R 24 Each of R can be independently hydrogen or an organyl group, alternatively hydrogen or an organyl group consisting of an inert functional group, alternatively hydrogen or a hydrocarbyl group, alternatively an organyl group, alternatively an organyl group consisting of an inert functional group, alternatively a hydrocarbyl group, or alternatively hydrogen. In one aspect, a non-hydrogen R 21 , R 22 , R 23 , and / or R 24 The organyl groups that can be used are C1-C 20 , C1~C 15 , C1~C 10 , or a C1-C5 organyl group. In one embodiment, the non-hydrogen R 21 , R 22 , R 23 , and / or R 24 The organyl group consisting of an inactive functional group that can be used as the organyl group is an inactive functional group having a C1 to C 20 , C1~C 15 , C1~C 10 , or a C1-C5 organyl group. In one embodiment, the non-hydrogen R 21 , R 22 , R 23 , and / or R 24 The hydrocarbyl groups that can be used are C1-C 20 , C1~C 15 , C1~C 10 , or a C1 to C5 hydrocarbyl group.
[0053] In one embodiment, each non-hydrogen R of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine and / or bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex 21 , R 22 , R 23 , and / or R 24may be independently an alkyl group, a substituted alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an aryl group, a substituted aryl group, an aralkyl group, or a substituted aralkyl group; alternatively, an alkyl group or a substituted alkyl group, alternatively, a cycloalkyl group or a substituted cycloalkyl group, alternatively, an aryl group or a substituted aryl group, alternatively, an aralkyl group or a substituted aralkyl group, alternatively, an alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, alternatively, an alkyl group, alternatively, a substituted alkyl group, alternatively, a cycloalkyl group, alternatively, a substituted cycloalkyl group, alternatively, an aryl group, alternatively, a substituted aryl group, alternatively, an aralkyl group, or alternatively, a substituted aralkyl group. In any of the aspects disclosed herein, R 21 , R 22 , R 23 , and / or R 24 Each alkyl group is independently C1 to C 20 , C1~C 10 or a C1-C5 alkyl group. In any embodiment disclosed herein, R 21 , R 22 , R 23 , and / or R 24 Each of the substituted alkyl groups is independently C1 to C 20 , C1~C 10 or a C1-C5 substituted alkyl group. 21 , R 22 , R 23 , and / or R 24 Each cycloalkyl group is independently a C4-C 20 , C4~C 15 , or C4~C 10 In any embodiment disclosed herein, R 21 , R 22 , R 23 , and / or R 24 Each substituted cycloalkyl group is independently a C4-C 20 , C4~C 15 , or C4~C 10In any of the embodiments disclosed herein, R 21 , R 22 , R 23 , and / or R 24 Each aryl group is independently C6-C 20 , C6~C 15 , or C6~C 10 In any embodiment disclosed herein, R 21 , R 22 , R 23 , and / or R 24 Each substituted aryl group is independently C6-C 20 , C6~C 15 , or C6~C 10 In any embodiment disclosed herein, R 21 , R 22 , R 23 , and / or R 24 Each aralkyl group is independently C7-C 20 , C7~C 15 , or C7~C 10 In any embodiment disclosed herein, R 21 , R 22 , R 23 , and / or R 24 Each substituted aralkyl group is independently a C7-C 20 , C7~C 15 , or C7~C 10It may be a substituted aralkyl group. Each of the substituents of the substituted alkyl group (general or specific), substituted cycloalkyl group (general or specific), substituted aryl group (general or specific), and / or substituted aralkyl group (general or specific) may be a halogen, a hydrocarbyl group, or a hydrocarboxy group, alternatively a halogen or a hydrocarbyl group, alternatively a halogen or a hydrocarboxy group, alternatively a hydrocarbyl group or a hydrocarboxy group, alternatively a halogen, alternatively a hydrocarbyl group, or alternatively a hydrocarboxy group. The substituent halogen, the substituent hydrocarbyl group (general and specific), and the substituent hydrocarboxy group (general and specific) are independently disclosed herein. Such substituent halogen, the substituent hydrocarbyl group, and the substituent hydrocarboxy group may be utilized without limitation to form the substituted non-hydrogen R 21 , R 22 , R 23 , and / or R 24 can be further explained.
[0054] In one embodiment, R of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine structure and the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex structure 21 , R 22 , R 23 , and / or R 24 are not hydrogen, each non-hydrogen R of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine and / or bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex 21 , R 22 , R 23 , and / or R 24 can be independently a methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl group, or alternatively a methyl, ethyl, n-propyl (1-propyl), iso-propyl (2-propyl), tert-butyl (2-methyl-2-propyl), or neopentyl (2,2-dimethyl-1-propyl) group. 21 , R 22 , R23 , and / or R 24 The alkyl groups that may be utilized as R may be substituted. Each substituent of the substituted alkyl groups (general or specific) may independently be a halogen or a hydrocarboxy group, alternatively a halogen, or alternatively a hydrocarboxy group. The substituent halogen and the substituent hydrocarboxy groups (general and specific) are independently disclosed herein. Such substituent halogen and substituent hydrocarboxy groups may be utilized without limitation to substitute for non-hydrogen R 21 , R 22 , R 23 , and / or R 24 The substituted alkyl groups that can be utilized as the alkyl group can be further described.
[0055] In one embodiment, L 1 , L 2 , and / or L 3 Bicyclic 2-[(phosphinyl)aminyl]cyclic imine and bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complexes having the formula 1 , L 2 , and L 3 may independently be an organylene group, alternatively an organylene group consisting of an inert functional group, or alternatively a hydrocarbylene group. 1 , L 2 , and / or L 3 The organylene groups are independently C1 to C 20 , C1~C 15 , C1~C 10 or a C1-C5 organylene group. 1 , L 2 , and / or L 3 The organylene group is independently a C1-C aryl group consisting of an inert functional group. 20 , C1~C 15 , C1~C 10 or a C1-C5 organylene group. 1 , L 2 , and / or L 3 The hydrocarbylene groups are independently C1 to C 20 , C1~C 15, C1~C 10 , or a C1 to C5 hydrocarbylene group.
[0056] In one embodiment, L 1 , L 2 , and / or L 3 Bicyclic 2-[(phosphinyl)aminyl]cyclic imine and bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complexes having the formula 1 , L 2 , and / or L 3 may independently have any of the structures provided in Table 1. In some embodiments, L 1 , L 2 , and / or L 3 can have Structure 1L, Structure 2L, Structure 3L, Structure 4L, or Structure 5L. In some embodiments, L 1 and / or L 2 may have Structure 2L, Structure 3L, or Structure 4L, alternatively, Structure 5L or Structure 6L. 1 , L 2 , and / or L 3 may have Structure 1L, alternatively, Structure 2L, alternatively, Structure 3L, alternatively, Structure 4L, alternatively, Structure 5L, or alternatively, Structure 6L. [Table 1] In the structure of Table 1, L 1 , L 2 , and / or L 3 The unspecified valence of L 1 , L 2 , and / or L 3 represents the point of attachment to the designated atom of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine and / or bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex when present in the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex. 1 , L 2 , and / or L 3m for the linking group can independently be an integer ranging from 1 to 5, alternatively 1 to 3, alternatively 1, alternatively 2, or alternatively 3. In one embodiment, R of a linking group having Structure 1L or Structure 2L is L1 and R L2 , R of a linking group having structure 3L L3 , R L4 , R L5 , and R L6 , R of a linking group having structure 4L L3 , R L4 , R L5 , R L6 , R L7 , and R L8 , R of a linking group having structure 5L L11 and R L12 and R of the linking group having structure 6L L21 , R L22 , R L23 , and R L24 may be independently hydrogen or a non-hydrogen substituent, or alternatively hydrogen. The non-hydrogen substituents (general and specific) are independently disclosed herein and may be utilized without limitation to further describe linking groups having Structure 1L, Structure 2L, Structure 3L, Structure 4L, Structure 5L, and / or Structure 6L. In one aspect, L 1 , L 2 , and / or L 3are independently a methylene group (-CH2-), an eth-1,2-ylene group (-CH2CH2-), an ethene-1,2-ylene group (-CH=CH-), a prop-1,3-ylene group (-CH2CH2CH2-), a prop-1,2-ylene group (-CH(CH3)CH2-), a propen-1,3-ylene group (-CH2CH=CH-), a propen-1,2-ylene group (-CH=CH(CH3)-), a but-1,4-ylene group (-CH2CH2CH2CH2-), a but-1,3-ylene group (-CH2CH2CH (CH3)-), a 2-methylprop-1,3-ylene group (-CH2CH(CH3)CH2-), a 2-methylprop-1,2-ylene group (-C(CH3)2CH2-), a but-1,2-en-1,4-ylene group (-CH2CH2CH=CH-), a but-1,2-en-1,3-ylene group (-CH(CH3)CH=CH-), a but-2,3-en-1,4-ylene group (-CH2CH=CHCH2-), or a 2-methylpropen-1,3-ylene group (-CH2C(CH3)=CH-). In some non-limiting embodiments, L 1 and / or L 2are methylene group (-CH2-), eth-1,2-ylene group (-CH2CH2-), ethene-1,2-ylene group (-CH=CH-), propane-1,3-ylene group (-CH2CH2CH2-), -), propane-1,2-ylene group (-CH(CH3)CH2-), propane-1,3-ylene group (-CH2CH=CH-), propane-1,2-ylene group (-CH=CH(C H3)-), but-1,3-ylene group (-CH2CH2CH(CH3)-), 2-methylprop-1,3-ylene group (-CH2CH(CH3)CH2-), 2-methylprop-1,2-ylene group (-C(CH3)2CH2-), or 2-methylpropen-1,3-ylene group (-CH2C(CH3)=CH-), alternatively methylene group (-CH2-), eth-1 ,2-ylene group (-CH2CH2-), prop-1,3-ylene group (-CH2CH2CH2-), prop-1,2-ylene group (-CH(CH3)CH2-), but-1,3-ylene group (-CH2CH2CH(CH3)-), 2-methylprop-1,3-ylene group (-CH2CH(CH3)CH2-), or 2-methylprop-1,2-ylene group (-C(CH3 )2CH2-), alternatively a methylene group (-CH2-), an eth-1,2-ylene group (-CH2CH2-), or a prop-1,3-ylene group (-CH2CH2CH2-), alternatively a methylene group (-CH2-), alternatively an eth-1,2-ylene group (-CH2CH2-), or alternatively a prop-1,3-ylene group (-CH2CH2CH2-). 1 , L 2 , and / or L 3are given appropriate names. However, such appropriate names are not intended to imply to which atoms of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine and / or bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex the unspecified valences are attached. Unless otherwise specified, the unspecified valences may be attached to either of the two bicyclic 2-[(phosphinyl)aminyl]cyclic imine designated atoms or the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex designated atoms, provided that this results in the appropriate bicyclic 2-[(phosphinyl)aminyl]cyclic imine or bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex.
[0057] Generally, R of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine and / or bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex 4 and / or R 5 may be independently an organyl group, alternatively an organyl group consisting of an inert functional group, or alternatively a hydrocarbyl group. 4 and / or R 5 Organyl groups are C1-C 20 , C1~C 15 , C1~C 10 or a C1-C5 organyl group. In one embodiment, R 4 and / or R 5 Organyl groups are C1-C groups consisting of inactive functional groups. 20 , C1~C 15 , C1~C 10 or a C1-C5 organyl group. 4 and / or R 5 The hydrocarbyl group is C1-C 20 , C1~C 15 , C1~C 10 or a C1-C5 hydrocarbyl group. In one embodiment, R of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine and / or the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex may be 4 and / or R5 may be independently an alkyl group, a substituted alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an aryl group, a substituted aryl group, an aralkyl group, or a substituted aralkyl group; alternatively, an alkyl group or a substituted alkyl group, alternatively, a cycloalkyl group or a substituted cycloalkyl group, alternatively, an aryl group or a substituted aryl group, alternatively, an aralkyl group or a substituted aralkyl group; alternatively, an alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group; alternatively, an alkyl group, alternatively, a substituted alkyl group, alternatively, a cycloalkyl group, alternatively, a substituted cycloalkyl group, alternatively, an aryl group, alternatively, a substituted aryl group, alternatively, an aralkyl group, or alternatively, a substituted aralkyl group.
[0058] In any embodiment disclosed herein, R 4 and / or R 5 The alkyl group is independently C1 to C 20 , C1~C 10 or a C1-C5 alkyl group. In any embodiment disclosed herein, R 4 and / or R 5 The substituted alkyl groups are independently C1 to C 20 , C1~C 10 or a C1-C5 substituted alkyl group. 4 and / or R 5 The cycloalkyl groups are independently C4 to C 20 , C4~C 15 , or C4~C 10 In any embodiment disclosed herein, R 4 and / or R 5 The substituted cycloalkyl group is independently C4-C 20 , C4~C 15 , or C4~C 10 In any of the embodiments disclosed herein, R 4 and / or R 5 The aryl groups are independently C6 to C 20 , C6~C 15, or C6~C 10 In any embodiment disclosed herein, R 4 and / or R 5 The substituted aryl groups are independently C6 to C 20 , C6~C 15 , or C6~C 10 In any embodiment disclosed herein, R 4 and / or R 5 The aralkyl groups are independently C7 to C 20 , C7~C 15 , or C7~C 10 In any embodiment disclosed herein, R 4 and / or R 5 The substituted aryl groups are independently C7 to C 20 , C7~C 15 , or C7~C 10 It may be a substituted aralkyl group. Each of the substituents of the substituted alkyl group (general or specific), substituted cycloalkyl group (general or specific), substituted aryl group (general or specific), and / or substituted aralkyl group (general or specific) may be a halogen, a hydrocarbyl group, or a hydrocarboxy group, alternatively a halogen or a hydrocarbyl group, alternatively a halogen or a hydrocarboxy group, alternatively a hydrocarbyl group or a hydrocarboxy group, alternatively a halogen, alternatively a hydrocarbyl group, or alternatively a hydrocarboxy group. The substituent halogen, the substituent hydrocarbyl group (general and specific), and the substituent hydrocarboxy group (general and specific) are independently disclosed herein. Such substituent halogen, the substituent hydrocarbyl group, and the substituent hydrocarboxy group are utilized without limitation and may be included in R 4 and / or R 5 can be further explained.
[0059] In one embodiment, R 4 and R 5can be independently a methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl group, or alternatively a methyl, ethyl, n-propyl (1-propyl), iso-propyl (2-propyl), 2-methyl-1-propyl, tert-butyl (2-methyl-2-propyl), or neopentyl (2,2-dimethyl-1-propyl) group. 4 and / or R 5 The alkyl groups that may be utilized as R may be substituted. Each substituent of the substituted alkyl group may independently be a halogen or a hydrocarboxy group, alternatively a halogen, or alternatively a hydrocarboxy group. The substituent halogen and the substituent hydrocarboxy groups (general and specific) are independently disclosed herein. Such substituent halogen and substituent hydrocarboxy groups may be utilized without limitation to form R 4 and / or R 5 The substituted alkyl groups that can be utilized as the alkyl group can be further described.
[0060] In one embodiment, R 4 and R 5 may be independently a cyclopentyl group, a substituted cyclopentyl group, a cyclohexyl group, or a substituted cyclohexyl group, alternatively a cyclopentyl group or a substituted cyclopentyl group, or alternatively a cyclohexyl group or a substituted cyclohexyl group. 4 and / or R 5The substituted cycloalkyl groups that may be utilized may be 2-substituted cyclohexyl groups, 2,6-disubstituted cyclohexyl groups, 2-substituted cyclopentyl groups, or 2,5-disubstituted cyclopentyl groups, alternatively 2-substituted cyclohexyl groups or 2,6-disubstituted cyclohexyl groups, alternatively 2-substituted cyclopentyl groups or 2,5-disubstituted cyclopentyl groups, alternatively 2-substituted cyclohexyl groups or 2-substituted cyclopentyl groups, or alternatively 2,6-disubstituted cyclohexyl groups or 2,5-disubstituted cyclopentyl groups. When a substituted cycloalkyl group (general or specific) has multiple substituents, the substituents may be the same or different, alternatively the same, or alternatively different. Each substituent of a cycloalkyl group (general or specific) having a particular number of ring carbon atoms may independently be a halogen, a hydrocarbyl group, or a hydrocarboxy group, alternatively a halogen or a hydrocarbyl group, alternatively a halogen or a hydrocarboxy group, alternatively a hydrocarbyl group or a hydrocarboxy group, alternatively a halogen, alternatively a hydrocarbyl group, or alternatively a hydrocarboxy group. The substituent halogens, substituent hydrocarbyl groups (general and specific), and substituent hydrocarboxy groups (general and specific) are independently disclosed herein. Such substituent halogens, substituent hydrocarbyl groups, and substituent hydrocarboxy groups are utilized without limitation to form R 4 and / or R 5 The substituted cycloalkyl groups (general or specific) that may be utilized as the cycloalkyl group may be further described.
[0061] In one non-limiting aspect, R 4 and R 5 may be independently a cyclohexyl, 2-alkylcyclohexyl, or 2,6-dialkylcyclohexyl group, or alternatively a cyclopentyl, 2-alkylcyclopentyl, or 2,5-dialkylcyclopentyl group. The alkyl substituents (general and specific) are independently described herein, and such alkyl substituents may be utilized without limitation to represent R 4 and / or R5 The alkylcyclohexyl groups (generic or specific), dialkylcyclohexyl groups (generic or specific), alkylcyclopentyl groups (generic or specific), and / or dialkylcyclopentyl groups (generic or specific) that may be utilized as R may be further described. In general, the alkyl substituents of the disubstituted cyclohexyl or disubstituted cyclopentyl groups may be the same, or alternatively, the alkyl substituents of the dialkylcyclohexyl or dialkylcyclopentyl groups may be different. In some non-limiting embodiments, R 4 and R 5 can be independently a 2-methylcyclohexyl group, a 2-ethylcyclohexyl group, a 2-isopropylcyclohexyl group, a 2-tert-butylcyclohexyl group, a 2,6-dimethylcyclohexyl group, a 2,6-diethylcyclohexyl group, a 2,6-diisopropylcyclohexyl group, or a 2,6-di-tert-butylcyclohexyl group. 4 and R 5 may be independently a 2-methylcyclohexyl, 2-ethylcyclohexyl, 2-isopropylcyclohexyl, or 2-tert-butylcyclohexyl group, or alternatively a 2,6-dimethylcyclohexyl, 2,6-diethylcyclohexyl, 2,6-diisopropylcyclohexyl, or 2,6-di-tert-butylcyclohexyl group.
[0062] In one embodiment, R 4 and R 5 may independently be a phenyl group, a substituted phenyl group, alternatively a phenyl group, or alternatively a substituted phenyl group. In one aspect, R 4 and / or R 5The substituted phenyl groups that may be utilized may be 2-substituted phenyl groups, 3-substituted phenyl groups, 4-substituted phenyl groups, 2,4-disubstituted phenyl groups, 2,6-disubstituted phenyl groups, 3,5-disubstituted phenyl groups, or 2,4,6-trisubstituted phenyl groups, alternatively 2-substituted phenyl groups, 4-substituted phenyl groups, 2,4-disubstituted phenyl groups, or 2,6-disubstituted phenyl groups, alternatively 3-substituted phenyl groups or 3,5-disubstituted phenyl groups, alternatively 2-substituted phenyl groups or 4-substituted phenyl groups, alternatively 2,4-disubstituted phenyl groups or 2,6-disubstituted phenyl groups, or alternatively 2,4,6-trisubstituted phenyl groups. When a substituted phenyl group (general or specific) has multiple substituents, the substituents may be the same or different, alternatively all of the substituents of a multiple substituted phenyl group may be the same, or alternatively all of the substituents of a multiple substituted phenyl group are different. Each substituent of the substituted phenyl group (general or specific) may independently be a halogen, a hydrocarbyl group, or a hydrocarboxy group; alternatively, a halogen or a hydrocarbyl group; alternatively, a halogen or a hydrocarboxy group; alternatively, a hydrocarbyl group or a hydrocarboxy group; alternatively, a halogen, alternatively, a hydrocarbyl group, or alternatively, a hydrocarboxy group. The substituent halogens, the substituent hydrocarbyl groups (general and specific), and the substituent hydrocarboxy groups (general and specific) are independently disclosed herein. Such substituent halogens, substituent hydrocarbyl groups, and substituent hydrocarboxy groups are utilized without limitation to form R 4 and / or R 5 The substituted phenyl groups (general or specific) that may be utilized as the phenyl group may be further described.
[0063] In one non-limiting aspect, R 4 and R 5may be independently a phenyl group, a 2-alkylphenyl group, a 3-alkylphenyl group, a 4-alkylphenyl group, a 2,4-dialkylphenyl group, a 2,6-dialkylphenyl group, a 3,5-dialkylphenyl group, or a 2,4,6-trialkylphenyl group, alternatively a 2-alkylphenyl group, a 4-alkylphenyl group, a 2,4-dialkylphenyl group, a 2,6-dialkylphenyl group, or a 2,4,6-trialkylphenyl group, alternatively a 2-alkylphenyl group or a 4-alkylphenyl group, alternatively a 2,4-dialkylphenyl group or a 2,6-dialkylphenyl group, alternatively a 3-alkylphenyl group or a 3,5-dialkylphenyl group, alternatively a 2-alkylphenyl group or a 2,6-dialkylphenyl group, or alternatively a 2,4,6-trialkylphenyl group. The alkyl substituents (general and specific) are independently described herein and such alkyl substituents may be utilized without limitation to describe R 4 and / or R 5 In general, the alkyl substituents of the dialkylphenyl group (generic or specific) or trialkylphenyl group (generic or specific) can be the same, or alternatively, the alkyl substituents of the dialkylphenyl group (generic or specific) or trialkylphenyl group (generic or specific) can be different. In some non-limiting embodiments, R 4 and R 5may be independently phenyl, 2-methylphenyl, 2-ethylphenyl, 2-n-propylphenyl, 2-isopropylphenyl, 2-tert-butylphenyl, 2,6-dimethylphenyl, 2,6-diethylphenyl, 2,6-di-n-propylphenyl, 2,6-diisopropylphenyl, 2,6-di-tert-butylphenyl, 2-isopropyl-6-methylphenyl, or 2,4,6-trimethylphenyl; alternatively phenyl, 2-methylphenyl, 2-ethylphenyl, 2-n-propylphenyl, 2-isopropylphenyl, or 2-tert-butylphenyl; alternatively phenyl, 2,6-dimethylphenyl, 2,6-diethylphenyl, 2,6-di-n-propylphenyl, 2,6-diisopropylphenyl, 2,6-di-tert-butylphenyl, 2-isopropyl-6-methylphenyl, or 2,4,6-trimethylphenyl.
[0064] In one non-limiting aspect, R 4 and R 5 can be a phenyl group, a 2-alkoxyphenyl group, or a 4-alkoxyphenyl group. In some non-limiting embodiments, R 4 and / or R 5 can be a phenyl group, a 2-methoxyphenyl group, a 2-ethoxyphenyl group, a 2-isopropoxyphenyl group, a 2-tert-butoxyphenyl group, a 4-methoxyphenyl group, a 4-ethoxyphenyl group, a 4-isopropoxyphenyl group, or a 4-tert-butoxyphenyl group, alternatively a 2-methoxyphenyl group, a 2-ethoxyphenyl group, a 2-isopropoxyphenyl group, or a 2-tert-butoxyphenyl group, or alternatively a 4-methoxyphenyl group, a 4-ethoxyphenyl group, a 4-isopropoxyphenyl group, or a 4-tert-butoxyphenyl group. 4 and R 5may independently be a phenyl group, a 2-halophenyl group, a 4-halophenyl group, or a 2,6-dihalophenyl group. In general, the halides of the dihalophenyl groups may be the same, or alternatively, the halides of the dihalophenyl groups may be different. In some embodiments, R 4 and R 5 can independently be a phenyl group, a 2-fluorophenyl group, a 4-fluorophenyl group, or a 2,6-difluorophenyl group.
[0065] In one embodiment, R 4 and R 5 may be independently a benzyl group or a substituted benzyl group, alternatively a benzyl group, or alternatively a substituted benzyl group. Each substituent of the substituted benzyl group may independently be a halogen, a hydrocarbyl group, or a hydrocarboxy group, alternatively a halogen or a hydrocarbyl group, alternatively a halogen or a hydrocarboxy group, alternatively a hydrocarbyl group or a hydrocarboxy group, alternatively a halogen, alternatively a hydrocarbyl group, or alternatively a hydrocarboxy group. The substituent halogens, substituent hydrocarbyl groups (general and specific), and substituent hydrocarboxy groups (general and specific) are independently disclosed herein. Such substituent halogens, substituent hydrocarbyl groups, and substituent hydrocarboxy groups are utilized without limitation to form R 4 and / or R 5 The following further illustrates the substituted benzyl that can be utilized as the compound:
[0066] In another embodiment, R 4 and R 5 may be linked to form a ring or ring system that includes a phosphorus atom. 4 and R 5 The link is L 45 and may be an organylene group, alternatively an organylene group consisting of an inert functional group, alternatively a hydrocarbylene group, or alternatively an alkylene group. 45 Organylene groups, if present, are C4-C 30 , C4~C20 , C4~C 15 , or C4~C 10 In one embodiment, L may be an organylene group. 45 The organylene group, if present, is a C4-C alkyl group consisting of an inert functional group. 30 , C4~C 20 , C4~C 15 , or C4~C 10 In one embodiment, L may be an organylene group. 45 The hydrocarbyl groups, if present, are independently C4 to C 30 , C4~C 20 , C4~C 15 , or C4~C 10 In another embodiment, L 45 Alkylene groups, if present, are independently C4 to C 30 , C4~C 20 , C4~C 15 , or C4~C 10 In one embodiment, L may be an alkylene group. 45 may be a but-1,4-ylene group, a 1,4-diphenylbut-1,4-ylene group, a 1,4-di(2-methylphenyl)but-1,4-ylene group, a 1,4-di(4-methylphenyl)but-1,4-ylene group, a 1,4-di(4-t-butylphenyl)but-1,4-ylene group, a 1,4-di(3,5-dimethylphenyl)but-1,4-ylene group, a penta-1,4-ylene group, a 1-phenylpent-1,4-ylene group, a 4-phenylpent-1,4-ylene group, a hexa-2,5-ylene group, a 2,2'-biphenylene group, a 2,2'-(methanediyl)diphenylene group, or a 2,2'-(1,2-ethanediyl)diphenylene group.
[0067] In various embodiments described herein, reference is made to non-hydrogen substituents, such as halogen (or halo, halide), hydrocarbyl, hydrocarboxy, alkyl, and / or alkoxy substituents. In one embodiment, each non-hydrogen substituent of any embodiment requiring a substituent can be a halogen, a hydrocarbyl group, or a hydrocarboxy group; alternatively, a halogen or a hydrocarbyl group; alternatively, a halogen or a hydrocarboxy group; alternatively, a hydrocarbyl group or a hydrocarboxy group; alternatively, a halogen, alternatively, a hydrocarbyl group, or alternatively, a hydrocarboxy group. Each hydrocarbyl substituent is independently a C1-C 10 Each hydrocarboxy substituent may independently be a C1-C5 hydrocarbyl group, or alternatively a C1-C5 hydrocarbyl group. 10 Each halide substituent may independently be a fluoride, chloride, bromide, or iodide, alternatively a fluoride or chloride, alternatively a fluoride, alternatively a chloride, alternatively a bromide, or alternatively an iodide.
[0068] In one aspect, any hydrocarbyl substituent may be independently an alkyl group, an aryl group, or an aralkyl group, alternatively an alkyl group, alternatively an aryl group, or alternatively an aralkyl group. In one aspect, any alkyl substituent may be independently a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a 2-pentyl group, a 3-pentyl group, a 2-methyl-1-butyl group, a tert-pentyl group, a 3-methyl-1-butyl group, a 3-methyl-2-butyl group, or a neo-pentyl group, alternatively a methyl group, an ethyl group, an isopropyl group, a tert-butyl group, or a neo-pentyl group, alternatively a methyl group, an ethyl group, an isopropyl group, an alternatively a tert-butyl group, or alternatively a neo-pentyl group. In one aspect, any aryl substituent may independently be a phenyl group, a tolyl group, a xylyl group, or a 2,4,6-trimethylphenyl group, alternatively a phenyl group, alternatively a tolyl group, alternatively a xylyl group, or alternatively a 2,4,6-trimethylphenyl group. In one aspect, any aralkyl substituent may independently be a benzyl group or an ethylphenyl group (2-phenyleth-1-yl or 1-phenyleth-1-yl), alternatively a benzyl group, alternatively an ethylphenyl group, alternatively a 2-phenyleth-1-yl group, or alternatively a 1-phenyleth-1-yl group.
[0069] In one aspect, any hydrocarboxy substituents may independently be an alkoxy group, an aryloxy group, or an aralkoxy group, alternatively an alkoxy group, alternatively an aryloxy group, or an aralkoxy group. In one aspect, any alkoxy substituent may independently be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, 2-methyl-1-butoxy, tert-pentoxy, 3-methyl-1-butoxy, 3-methyl-2-butoxy, or neo-pentoxy; alternatively, methoxy, ethoxy, isopropoxy, tert-butoxy, or neo-pentoxy; alternatively, methoxy, alternatively, ethoxy, alternatively, isopropoxy, alternatively, tert-butoxy, or alternatively, neo-pentoxy. In one aspect, any aryloxy substituent may be independently a phenoxy, troxy, xyloxy, or 2,4,6-trimethylphenoxy group, alternatively a phenoxy group, alternatively a troxy group, alternatively a xyloxy group, or alternatively a 2,4,6-trimethylphenoxy group. In one aspect, any aralkoxy substituent may be independently a benzoxy group.
[0070] Various embodiments disclosed herein may utilize a chromium salt or a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex. Generally, the chromium salt of the chromium salt and / or the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex is CrX pwhere X represents a monoanionic ligand and p represents the number of monoanionic ligands (and the oxidation state of chromium in the chromium compound). The monoanionic ligand (X) and p are independent elements of the chromium salt and the chromium salt portion of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex, and are described independently herein. These independent descriptions of the monoanionic ligand (X) and p may be utilized in any combination, without limitation, to further describe the chromium salt and / or the chromium salt of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex that may be utilized in the various embodiments described herein.
[0071] Generally, chromium salts (CrX p The chromium atom of the chromium salt of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex may have any positive oxidation state available to the chromium atom. In one embodiment, the chromium atom may have an oxidation state of +2 to +6, alternatively +2 to +4, or alternatively +2 to +3. In some embodiments, the chromium compound (CrX p The chromium atom in may have an oxidation state of +1, alternatively +2, alternatively +3, or alternatively +4.
[0072] The monoanion X of the chromium salt and / or the chromium salt of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex can be any monoanion. In one embodiment, the monoanion (X) can be a halide, carboxylate, β-diketonate, hydrocarboxylate, nitrate, or chlorate. In some embodiments, the monoanion (X) can be a halide, carboxylate, β-diketonate, or hydrocarboxylate. In any embodiment, the hydrocarboxylate can be an alkoxide, aryloxide, or aralkoxide. In general, the hydrocarboxylate (and subclasses of hydrocarboxylate) are anionic analogs of the hydrocarboxy group. In other embodiments, the monoanion (X) can be a halide, carboxylate, β-diketonate, or alkoxide, or alternatively, a halide or β-diketonate. In other embodiments, the monoanion (X) can be a halide, alternatively a carboxylate, alternatively a β-diketonate, alternatively a hydrocarboxylate, alternatively an alkoxide, or alternatively an aryloxide. In one embodiment, the number of monoanions can be 2 to 6, alternatively 2 to 4, alternatively 2 to 3, alternatively 1, alternatively 2, alternatively 3, or alternatively 4.
[0073] Generally, chromium salts (CrX p Each halide of the chromium salt of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex can be independently fluorine, chlorine, bromine, or iodine, or alternatively chlorine, bromine, or iodine. In one aspect, each halide monoanion of the chromium compound can be chlorine, alternatively bromine, or alternatively iodine.
[0074] Generally, chromium salts (CrX p ) or each carboxylate of the chromium salt of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex is independently C1-C 20 Or C1~C 10In one aspect, each carboxylate can independently be acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, octanoate, nonanoate, decanoate, undecanoate, or dodecanoate, or alternatively, pentanoate, hexanoate, heptanoate, octanoate, nonanoate, decanoate, undecanoate, or dodecanoate. In some embodiments, each carboxylate is independently selected from acetate, propionate, n-butyrate, valerate (n-pentanoate), neo-pentanoate, capronate (n-hexanoate), n-heptanoate, caprylate (n-octanoate), 2-ethylhexanoate, n-nonanoate, caprate (n-decanoate), n-undecanoate, or laurate (n-dodecanoate), alternatively, valerate (n-pentanoate), neo-pentanoate, capronate (n-hexanoate), n-heptanoate, caprylate (n-octanoate), 2-ethylhexanoate, n-nonanoate, caprate (n-decanoate), n-undecanoate, or laurate (n-dodecanoate). It may be o-pentanoate, capronate (n-hexanoate), n-heptanoate, caprylate (n-octanoate), 2-ethylhexanoate, n-nonanoate, caprate (n-decanoate), n-undecanoate, or laurate (n-dodecanoate), alternatively capronate (n-hexanoate), alternatively n-heptanoate, alternatively caprylate (n-octanoate), or alternatively 2-ethylhexanoate. In some embodiments, each carboxylate may be a triflate (trifluoroacetate).
[0075] Generally, chromium salts (CrX p ) or bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex, each β-diketonate is independently selected from C1 to C 20 Or C1~C 10In one aspect, each β-diketonate can be independently an acetylacetonate (i.e., 2,4-pentanedionate), a hexafluoroacetylacetonate (i.e., 1,1,1,5,5,5-hexafluoro-2,4-pentanedionate), or a benzoylacetonate, alternatively an acetylacetonate, alternatively a hexafluoroacetylacetonate, or alternatively a benzoylacetonate.
[0076] Generally, chromium salts (CrX p ) or bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex, each hydrocarboxylate is independently selected from C1 to C 20 Or C1~C 10 In one embodiment, each hydrocarboxyl group can be independently selected from the group consisting of C1 to C 20 Or C1~C 10 Alkoxides, or alternatively, C6-C 20 Or C6~C 10 In one aspect, each alkoxide can be independently methoxide, ethoxide, propoxide, or butoxide, alternatively methoxide, ethoxide, isopropoxide, or tert-butoxide, alternatively methoxide, alternatively ethoxide, alternatively isopropoxide, or alternatively tert-butoxide. In one aspect, the aryloxide can be a phenoxide.
[0077] In some non-limiting embodiments, chromium salts (CrX p ) or the chromium salt of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex can comprise, consist essentially of, or consist of a chromium(II) halide, a chromium(II) carboxylate, or a chromium(II) β-diketonate, or alternatively, a chromium(III) halide, a chromium(III) carboxylate, or a chromium(III) β-diketonate. In other non-limiting embodiments, the chromium salt (CrX p) or the chromium salt of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex may comprise, consist essentially of, or consist of a chromium(II) halide, alternatively a chromium(III) halide, alternatively a chromium(II) carboxylate, alternatively a chromium(III) carboxylate, alternatively a chromium(II) β-diketonate, or alternatively a chromium(III) β-diketonate. The halides, carboxylates, β-diketonates are independently described herein, and such halides, carboxylates, β-diketonates, and such independently described halides, carboxylates, β-diketonates may be utilized in any combination, without limitation, to produce a chromium salt (CrX p ) or a bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex. In a further non-limiting embodiment, the chromium salt (CrX p) or bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complexes include chromium(II) chloride, chromium(III) chloride, chromium(II) fluoride, chromium(III) fluoride, chromium(II) bromide, chromium(III) bromide, chromium(II) iodide, chromium(III) iodide, chromium(II) acetate, chromium(III) acetate, chromium(II) 2-ethylhexanoate, chromium(III) 2-ethylhexanoate, chromium(II) triflate, chromium(III) triflate, chromium(II) nitrate, chromium(III) nitrate, chromium(II) acetylacetonate, chromium(III) acetylacetonate, chromium(II) hexafluoroacetylacetonate, chromium(III) hexafluoroacetylacetonate, chromium(III) benzoylacetonate, chromium(III) acetylacetonate, or chromium(III) benzoylacetonate; alternatively, chromium(III) chloride, chromium(III) fluoride, chromium(III) bromide, chromium(III) iodide, chromium(III) chloride (THF) complex, chromium(III) acetate, chromium(III) 2-ethylhexanoate, chromium(III) triflate, chromium(III) nitrate, chromium(III) acetylacetonate, chromium(III) hexafluoroacetylacetonate, or chromium(III) benzoylacetonate; alternatively, chromium(III) chloride, or chromium(III) acetylacetonate; alternatively, chromium(III) chloride, or alternatively, chromium(III) acetylacetonate.
[0078] In one aspect, the bicyclic 2-[(phosphinyl)aminyl]cyclic imine can have the structure BPACI1, BPACI2, BPACI3, or BPACI4, alternatively the structure BPACI1, alternatively the structure BPACI2, alternatively the structure BPACI3, or alternatively the structure BPACI4. [ka] In one embodiment, the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex can have the structure BPACICr1, BPACICr2, BPACICr3, or BPACICr4, alternatively the structure BPACICr1, alternatively the structure BPACICr2, alternatively the structure BPACICr3, or alternatively the structure BPACICr4. [ka]
[0079] Although the chromium salt is not specified and is not shown in the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex structures provided herein, one of skill in the art will recognize that the chromium salts, bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes described / illustrated / provided herein may be associated with a neutral ligand Q. Furthermore, although the presence of a neutral ligand is not formally shown in the chromium salts and bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes described / illustrated / provided herein, it is understood that chromium salts and / or bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes having neutral ligands (e.g., nitriles and ethers, among others) are implicitly and fully contemplated as possible chromium salts and / or bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes that may be utilized in the catalyst systems used in the embodiments of the invention described herein.
[0080] In general, the neutral ligands of any chromium salt and / or bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex, if present, can be any neutral ligand that independently forms an isolable compound with the chromium salt and / or bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex. In one aspect, each neutral ligand can independently be a nitrile or ether, alternatively a nitrile, or alternatively an ether. The number of neutral ligands q can be any number that independently forms an isolable compound with the chromium salt and / or bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex. In one aspect, the number of neutral ligands can be 0-6, alternatively 0-3, alternatively 0, alternatively 1, alternatively 2, alternatively 3, or alternatively 4.
[0081] Generally, each nitrile ligand is independently a C2-C 20 Or C2~C 10 In one embodiment, each nitrile ligand is independently a C2-C 20 Aliphatic nitriles, C7-C 20 Aromatic nitriles, C8-C 20 or any combination thereof; alternatively, C2-C 20 Aliphatic nitriles, alternatively C7-C 20 Aromatic nitriles, or alternatively, C-C 20 In some embodiments, each nitrile ligand is independently a C2-C 10 Aliphatic nitriles, C7-C 10 Aromatic nitriles, C8-C 10 or any combination thereof, alternatively C1-C 10 Aliphatic nitriles, alternatively C7-C 10 Aromatic nitriles, or alternatively, C-C 10In one aspect, each aliphatic nitrile can be independently acetonitrile, propionitrile, butyronitrile, benzonitrile, or any combination thereof, alternatively acetonitrile, alternatively propionitrile, alternatively butyronitrile, or alternatively benzonitrile.
[0082] Generally, each ether ligand is independently a C2-C 40 , C2~C 30 , or C2~C 20 In one embodiment, each ether ligand is independently a C2 to C 40 Aliphatic ethers, C3-C 40 Aliphatic cyclic ethers, C4-C 40 Aromatic cyclic ethers, alternatively C2-C 40 Aliphatic acyclic ether or C3-C 40 Aliphatic cyclic ethers, alternatively C2-C 40 Aliphatic acyclic ethers, alternatively C3-C 40 Aliphatic cyclic ethers, or alternatively, C4-C 40 In some embodiments, each ether ligand can be independently a C2 to C6 aromatic cyclic ether. 30 Aliphatic ethers, C3-C 30 Aliphatic cyclic ethers, C4-C 30 Aromatic cyclic ethers, alternatively C2-C 30 Aliphatic acyclic ether or C3-C 30 Aliphatic cyclic ethers, alternatively C2-C 30 Aliphatic acyclic ethers, alternatively C3-C 30 Aliphatic cyclic ethers, or alternatively, C4-C 30 In another embodiment, each ether ligand is independently a C2 to C6 aromatic cyclic ether. 20 Aliphatic ethers, C3-C 20 Aliphatic cyclic ethers, C4-C 20 Aromatic cyclic ethers, alternatively C2-C 20 Aliphatic acyclic ether or C3-C 20 Aliphatic cyclic ethers, alternatively C2-C20 Aliphatic acyclic ethers, alternatively C3-C 20 Aliphatic cyclic ethers, or alternatively, C4-C 20 It may be an aromatic cyclic ether. In some embodiments, each ether ligand is independently dimethyl ether, diethyl ether, dipropyl ether, dibutyl ether, methyl ethyl ether, methyl propyl ether, methyl butyl ether, tetrahydrofuran, dihydrofuran, 1,3-dioxolane, tetrahydropyran, dihydropyran, pyran, dioxane, furan, benzofuran, isobenzofuran, dibenzofuran, diphenyl ether, ditolyl ether, or any combination thereof, alternatively dimethyl ether, diethyl ether, dipropyl ether, dibutyl ether, methyl ethyl ether, methyl propyl ether, methyl butyl ether, or any combination thereof, tetrahydrofuran, dihydrofuran, 1,3-dioxolane, tetrahydropyran, dihydropyran, pyran, dioxane, or any combination thereof. , furan, benzofuran, isobenzofuran, dibenzofuran, or any combination thereof, diphenyl ether, ditolyl ether, or any combination thereof, alternatively, dimethyl ether, alternatively, diethyl ether, alternatively, dipropyl ether, alternatively, dibutyl ether, alternatively, methyl ethyl ether, alternatively, methyl propyl ether, alternatively, methyl butyl ether, alternatively, tetrahydrofuran, alternatively dihydrofuran, alternatively 1,3-dioxolane, alternatively, tetrahydropyran, alternatively dihydropyran, alternatively pyran, alternatively dioxane, alternatively, furan, alternatively benzofuran, alternatively isobenzofuran, alternatively dibenzofuran, alternatively diphenyl ether, or alternatively ditolyl ether.
[0083] Throughout this disclosure, monomeric forms of bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes are shown. Although not expressly shown, it should be noted that bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes may exist as dimeric structures with two monoanionic ligands bridging two chromium atoms. Thus, although monomeric bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes are shown herein, such structures do not necessarily imply that dimeric forms of bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes with bridging monomeric ligands are not formed and / or utilized.
[0084] In one aspect, the organoaluminum compound that may be utilized in the catalyst systems and processes described herein may include an aluminoxane, an alkylaluminum compound, or any combination thereof, alternatively, an aluminoxane, or alternatively, an alkylaluminum compound. In one aspect, the alkylaluminum compound may be a trialkylaluminum, an alkylaluminum halide, an alkylaluminum alkoxide, or any combination thereof. In some aspects, the alkylaluminum compound may be a trialkylaluminum, an alkylaluminum halide, or any combination thereof, alternatively, a trialkylaluminum, an alkylaluminum alkoxide, or any combination thereof, or alternatively, a trialkylaluminum. In other aspects, the alkylaluminum compound may be a trialkylaluminum, alternatively, an alkylaluminum halide, or alternatively, an alkylaluminum alkoxide. In one non-limiting aspect, the aluminoxane is represented by Formula I: [ka] may have a repeat unit characterized by: where R' is a straight or branched chain alkyl group. The alkyl groups for the organoaluminum compounds are independently described herein and may be utilized without limitation to further describe the aluminoxanes having formula I. In general, n in formula I may be greater than 1, or alternatively greater than 2. In one embodiment, n may range from 2 to 15, or alternatively from 3 to 10.
[0085] In one aspect, each halide of any alkylaluminum halide disclosed herein can be independently a fluoride, chloride, bromide, or iodide, or alternatively a chloride, bromide, or iodide. In one aspect, each halide of any alkylaluminum halide disclosed herein can be a fluoride, alternatively a chloride, alternatively a bromide, or alternatively an iodide.
[0086] In one aspect, each alkyl group of any organoaluminum compound disclosed herein (especially alkylaluminum trialkylaluminum, alkylaluminum halide, alkylaluminum alkoxide, or aluminoxane) is independently selected from the group consisting of C1 to C6. 20 , C1~C 10 , or a C1-C6 alkyl group. In one embodiment, each alkyl group of any organoaluminum compound disclosed herein can be independently methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl, alternatively methyl, ethyl, butyl, hexyl, or octyl. In some embodiments, each alkyl group of any organoaluminum compound disclosed herein can be independently methyl, ethyl, n-propyl, n-butyl, iso-butyl, n-hexyl, or n-octyl, alternatively methyl, ethyl, n-butyl, or iso-butyl, alternatively methyl, alternatively ethyl, alternatively n-propyl, alternatively n-butyl, alternatively iso-butyl, alternatively n-hexyl, or alternatively n-octyl.
[0087] In one aspect, each alkoxide group of any alkylaluminum alkoxide disclosed herein is independently a C1-C 20 , C1~C 10 or a C1-C6 alkoxy group. In one aspect, each alkoxide group of any alkylaluminum alkoxide disclosed herein can independently be a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a hexoxy group, a heptoxy group, or an octoxy group, alternatively a methoxy group, an ethoxy group, a butoxy group, a hexoxy group, or an octoxy group. In some aspects, each alkoxide group of any alkylaluminum alkoxide disclosed herein can independently be a methoxy group, an ethoxy group, an n-propoxy group, an n-butoxy group, an iso-butoxy group, an n-hexoxy group, or an n-octoxy group; alternatively, a methoxy group, an ethoxy group, an n-butoxy group, or an iso-butoxy group; alternatively, a methoxy group, alternatively, an ethoxy group, alternatively, an n-propoxy group, alternatively, an n-butoxy group, alternatively, an iso-butoxy group, alternatively, an n-hexoxy group, or alternatively, an n-octoxy group.
[0088] In one non-limiting embodiment, useful trialkylaluminum compounds can include trimethylaluminum, triethylaluminum, tripropylaluminum, tributylaluminum, trihexylaluminum, trioctylaluminum, or mixtures thereof. In some non-limiting embodiments, useful trialkylaluminum compounds can include trimethylaluminum, triethylaluminum, tripropylaluminum, tri-n-butylaluminum, tri-isobutylaluminum, trihexylaluminum, tri-n-octylaluminum, or mixtures thereof, alternatively triethylaluminum, tri-n-butylaluminum, tri-isobutylaluminum, trihexylaluminum, tri-n-octylaluminum, or mixtures thereof, alternatively triethylaluminum, tri-n-butylaluminum, trihexylaluminum, tri-n-octylaluminum, or mixtures thereof. In other non-limiting aspects, useful trialkylaluminum compounds can include trimethylaluminum, alternatively, triethylaluminum, alternatively, tripropylaluminum, alternatively, tri-n-butylaluminum, alternatively, tri-isobutylaluminum, alternatively, trihexylaluminum, or alternatively, tri-n-octylaluminum.
[0089] In one non-limiting aspect, useful alkylaluminum halides can include diethylaluminum chloride, diethylaluminum bromide, ethylaluminum dichloride, ethylaluminum sesquichloride, and mixtures thereof. In some non-limiting aspects, useful alkylaluminum halides can include diethylaluminum chloride, ethylaluminum dichloride, ethylaluminum sesquichloride, and mixtures thereof. In other non-limiting aspects, useful alkylaluminum halides can include diethylaluminum chloride, alternatively diethylaluminum bromide, alternatively ethylaluminum dichloride, or alternatively ethylaluminum sesquichloride.
[0090] In one non-limiting embodiment, useful aluminoxanes can include methylaluminoxane (MAO), ethylaluminoxane, modified methylaluminoxane (e.g., MMAO), n-propylaluminoxane, isopropylaluminoxane, n-butylaluminoxane, sec-butylaluminoxane, iso-butylaluminoxane, t-butylaluminoxane, 1-pentylaluminoxane, 2-pentylaluminoxane, 3-pentylaluminoxane, isopentylaluminoxane, neopentylaluminoxane, or mixtures thereof. In some non-limiting embodiments, useful aluminoxanes can include methylaluminoxane (MAO), modified methylaluminoxane (e.g., MMAO), isobutylaluminoxane, t-butylaluminoxane, or mixtures thereof. In other non-limiting aspects, useful aluminoxanes can include methylaluminoxane (MAO), alternatively, ethylaluminoxane, alternatively, modified methylaluminoxane (e.g., MMAO), alternatively, n-propylaluminoxane, alternatively, isopropylaluminoxane, alternatively, n-butylaluminoxane, alternatively, sec-butylaluminoxane, alternatively, iso-butylaluminoxane, alternatively, t-butylaluminoxane, alternatively, 1-pentylaluminoxane, alternatively, 2-pentylaluminoxane, alternatively, 3-pentylaluminoxane, alternatively, isopentylaluminoxane, or alternatively, neopentylaluminoxane.
[0091] In one embodiment, the catalyst system can have any organoaluminum compound and a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex (or alternatively, a chromium salt of a bicyclic 2-[(phosphinyl)aminyl] cyclic imine) in a ratio that can form an active catalyst system. In one embodiment, the catalyst system can have a minimum aluminum of the organoaluminum compound:chromium of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex (or alternatively, the chromium of the chromium salt present with the bicyclic 2-[(phosphinyl)aminyl] cyclic imine) molar ratio (i.e., minimum Al:Cr molar ratio) of 10:1, 50:1, 75:1, or 100:1, and alternatively or additionally can have a maximum aluminum of the organoaluminum compound:chromium of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex (or alternatively, the chromium of the chromium salt present with the bicyclic 2-[(phosphinyl)aminyl] cyclic imine) molar ratio (i.e., maximum Al:Cr molar ratio) of 5,000:1, 3,000:1, 2,000:1, 1,500:1, or 1,000:1. In one embodiment, the catalyst system can have an Al:Cr molar ratio ranging from any minimum Al:Cr molar ratio disclosed herein to any maximum Al:Cr molar ratio disclosed herein. In one non-limiting embodiment, the Al:Cr molar ratio can range from 10:1 to 5,000:1, 50:1 to 3,000:1, 75:1 to 2,000:1, 100:1 to 2,000:1, or 100:1 to 1,000:1. Other Al:Cr molar ratio ranges that can be utilized will be readily apparent to one of skill in the art in light of the present disclosure.
[0092] When the catalyst system utilizes a bicyclic 2-[(phosphinyl)aminyl] cyclic imine, a chromium salt, and an organoaluminum compound, the catalyst system may have (or the catalyst system may be formed at) any equivalent ratio of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine to the chromium of the chromium salt that allows for the formation of an oligomeric product, the oligomeric product may be formed at that equivalent ratio, the reaction zone may have that equivalent ratio, or the reaction zone may be operated at that equivalent ratio. In one embodiment, the minimum molar ratio of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine to the chromium of the chromium salt may be 0.8:1, 0.9:1, or 0.95:1, and alternatively or additionally, the maximum molar ratio of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine to the chromium of the chromium salt may be 4:1, 2:1, 1.5:1, or 1.1:1. In one embodiment, the catalyst system can have (or the catalyst system can be formed at), the oligomeric product can be formed at, the reaction zone can have, or the reaction zone can be operated at, a molar ratio of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine:chromium of the chromium salt ranging from any minimum molar ratio of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine:chromium of the chromium salt disclosed herein to any maximum molar ratio of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine:chromium of the chromium salt disclosed herein. In non-limiting embodiments, the molar ratio of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine:chromium of the chromium salt can be within the range of 0.8:1 to 4:1, 0.9:1 to 2:1, 0.9:1 to 1.5:1, 0.95:1 to 1.5:1, or 0.95:1 to 1.1:1. Other bicyclic 2-[(phosphinyl)aminyl] cyclic imine:chromium of the chromium salt molar ratio ranges that can be utilized will be readily apparent to one of skill in the art in light of the present disclosure.
[0093] In an aspect, the process described herein may include a) contacting ethylene with a catalyst system and b) forming an oligomeric product. In some aspects, the process described herein may include a) contacting ethylene with hydrogen with a catalyst system and b) forming an oligomeric product. In some aspects, the oligomeric product may be formed under conditions capable of forming the oligomeric product. In some aspects, the oligomeric product may be formed in a reaction zone. In an aspect, the process may be an ethylene oligomerization process, alternatively an ethylene trimerization process, alternatively an ethylene tetramerization process, or alternatively an ethylene trimerization and tetramerization process. In an aspect, the catalyst system may be formed in an organic liquid medium. In an aspect, the oligomeric product may be formed in an organic reaction medium (or the reaction zone may include an organic reaction medium). In general, the organic liquid medium in which the catalyst system may be formed and the organic reaction medium in which the olefin and the catalyst system may be contacted (or alternatively, the oligomeric product may be formed) may be the same or alternatively different. The characteristics of the catalyst system, the conditions under which the oligomeric product may be formed (or alternatively, the conditions under which the reaction zone may be operated), the organic liquid medium, the organic reaction medium, and the oligomeric product are described herein independently and may be utilized in any combination, without limitation, to further describe the processes described herein.
[0094] In one aspect, the process described herein may include a) forming a catalyst system mixture comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex and an organoaluminum compound (or alternatively, forming a catalyst system mixture comprising a chromium salt and a bicyclic 2-[(phosphinyl)aminyl] cyclic imine, a chromium salt, and an organoaluminum compound); b) contacting the catalyst system mixture with ethylene; and c) forming an oligomeric product. In some aspects, the step of contacting the catalyst system mixture with ethylene may be a step of contacting the catalyst system mixture with ethylene and hydrogen. In some aspects, the catalyst system mixture may further comprise an organic liquid medium. In some aspects, the catalyst system mixture and ethylene and optionally hydrogen may be contacted in or with an organic reaction medium. In one aspect, the process may include a) forming a catalyst system mixture comprising or consisting essentially of a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex, an organoaluminum compound, and an organic liquid medium (or alternatively comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine, a chromium salt, an organoaluminum compound, and an organic liquid medium); b) contacting the catalyst system mixture with ethylene and an organic reaction medium; and c) forming an oligomeric product. In some aspects, contacting the catalyst system mixture with ethylene and an organic liquid medium may be contacting the catalyst system mixture with ethylene, an organic reaction medium, and hydrogen. In some aspects, the organic liquid medium and the organic reaction medium may be the same, or alternatively, the organic liquid medium and the organic reaction medium may be different. In some aspects, an oligomeric product may be formed in the reaction zone. In some aspects, an oligomeric product may be formed under conditions capable of forming an oligomeric product.The bicyclic 2-[(phosphinyl)aminyl] cyclic imines, chromium salts, bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes, organoaluminum compounds, organic liquid media, organic reaction media, conditions under which the oligomeric products may be formed (or alternatively, conditions under which the reaction zone may be operated), and characteristics of the oligomeric products (among other independently described catalyst system and process features) are described herein independently and may be utilized in any combination, without limitation, to further describe the processes disclosed herein.
[0095] In one embodiment, the process described herein may include a) forming a composition comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex (or alternatively comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine and a chromium salt); b) forming a mixture comprising ethylene and an organoaluminum compound; c) contacting the composition of step a) with the mixture of step b); and d) forming an oligomeric product. In some embodiments, the mixture comprising ethylene and an organoaluminum compound may further comprise hydrogen. In some embodiments, the composition comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex (or alternatively comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine and a chromium salt) may further comprise an organic liquid medium. In some embodiments, the mixture comprising ethylene, an organoaluminum compound, and optionally hydrogen may further comprise an organic reaction medium. In one aspect, the process may include: a) forming a composition comprising or consisting essentially of a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex and an organic liquid medium (or alternatively comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine, a chromium salt, and an organic liquid medium); b) forming a mixture comprising ethylene, an organoaluminum compound, optionally hydrogen, and an organic reaction medium; c) contacting the composition of step a) with the mixture of step b); and d) forming an oligomeric product. In some aspects, the organic liquid medium and the organic reaction medium may be the same, or alternatively, the organic liquid medium and the organic reaction medium may be different. In some aspects, the oligomeric product may be formed in a reaction zone. In some aspects, the oligomeric product may be formed under conditions capable of forming the oligomeric product.The bicyclic 2-[(phosphinyl)aminyl] cyclic imines, chromium salts, bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes, organoaluminum compounds, organic liquid media, organic reaction media, conditions under which the oligomeric products may be formed (or alternatively, conditions under which the reaction zone may be operated), and characteristics of the oligomeric products (among other compositions, mixtures, oligomeric products, and process characteristics) are described herein independently and may be utilized in any combination, without limitation, to further describe the processes described herein.
[0096] In one aspect, the process described herein can include a) contacting ethylene with a catalyst system comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex (or alternatively, contacting a bicyclic 2-[(phosphinyl)aminyl] cyclic imine and a chromium salt), and b) forming an oligomeric product in a reaction zone. In some aspects, the process described herein can include a) contacting ethylene with hydrogen and a catalyst system comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex (or alternatively, contacting a bicyclic 2-[(phosphinyl)aminyl] cyclic imine and a chromium salt), and b) forming an oligomeric product in a reaction zone. In other aspects, the processes described herein may include a) contacting ethylene with a catalyst system comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex and an organoaluminum compound (or alternatively, a bicyclic 2-[(phosphinyl)aminyl] cyclic imine, a chromium salt, and an organoaluminum compound); and b) forming an oligomeric product in the reaction zone. In yet other aspects, the processes described herein may include a) contacting ethylene with hydrogen with a catalyst system comprising a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex and an organoaluminum compound (or alternatively, contacting a bicyclic 2-[(phosphinyl)aminyl] cyclic imine, a chromium salt, and an organoaluminum compound); and b) forming an oligomeric product in the reaction zone. In an aspect, each process may further include forming a catalyst system mixture comprising catalyst system components. In some aspects, the catalyst system mixture may be (or may be formed in) an organic liquid medium. In other aspects of each process, the oligomeric product may be formed in an organic reaction medium (or the reaction zone may include an organic reaction medium). In some aspects, the organic liquid medium and the organic reaction medium may be the same, or alternatively, the organic liquid medium and the organic reaction medium may be different.The bicyclic 2-[(phosphinyl)aminyl] cyclic imines, chromium salts, bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes, organoaluminum compounds, organic liquid media, organic reaction media, conditions under which the oligomeric products may be formed (or alternatively, conditions under which the reaction zone may be operated), and characteristics of the oligomeric products (among other compositions, mixtures, oligomeric products, and process characteristics) are described herein independently and may be utilized in any combination, without limitation, to further describe the processes described herein.
[0097] In an embodiment, the process described herein may be a batch process or a continuous process. In some embodiments, the reaction zone of any process described herein may include any reactor capable of oligomerizing, trimerizing, tetramerizing, or trimerizing and tetramerizing ethylene to oligomeric products. In some embodiments, the reaction zone may include one or more reactors. In some embodiments, the reaction zone may include a stirred tank reactor, a plug flow reactor, or any combination thereof, alternatively a stirred tank reactor, or alternatively a plug flow reactor. In an embodiment, the reaction zone of any process described herein may include an autoclave reactor, a continuous stirred tank reactor, a loop reactor, a gas phase reactor, a solution reactor, a tubular reactor, a recycle reactor, a bubble reactor, or any combination thereof, alternatively an autoclave reactor, alternatively a stirred tank reactor, alternatively a loop reactor, alternatively a gas phase reactor, alternatively a solution reactor, alternatively a tubular reactor, alternatively a recycle reactor, or alternatively a bubble reactor. In some embodiments, a reaction zone may contain multiple reactors, or alternatively, only one reactor. When multiple reactors are present, each of the reactors may be the same, or alternatively, two or more of the reactors may be different. A reaction zone may contain a single or multiple reactors of any type disclosed herein operated in batch or continuous mode and / or in series or parallel.
[0098] The processes described herein may employ an organic liquid medium and / or an organic reaction medium. In general, the organic liquid medium and / or the organic reaction medium may act as a solvent and / or a diluent in the processes described herein. In one aspect, the organic liquid medium and / or the organic reaction medium may be a hydrocarbon, a halogenated hydrocarbon, or a combination thereof. Hydrocarbons and halogenated hydrocarbons that may be used as the organic liquid medium and / or the organic reaction medium may include, for example, aliphatic hydrocarbons, aromatic hydrocarbons, petroleum distillates, halogenated aliphatic hydrocarbons, halogenated aromatic hydrocarbons, or a combination thereof. Aliphatic hydrocarbons that may be used as the organic liquid medium and / or the organic reaction medium include, for example, C3-C 20 , C4~C 15 , or C5~C 10 Aliphatic hydrocarbons are included. Aliphatic hydrocarbons that can be used as organic liquid media and / or organic reaction media can be cyclic or acyclic, and / or linear or branched, unless otherwise specified. Non-limiting examples of suitable acyclic aliphatic hydrocarbon organic liquid media and / or organic reaction media that can be utilized include propane, isobutane, n-butane, butane (n-butane or a mixture of linear and branched C4 acyclic aliphatic hydrocarbons), pentane (n-pentane or a mixture of linear and branched C5 acyclic aliphatic hydrocarbons), hexane (n-hexane or a mixture of linear and branched C6 acyclic aliphatic hydrocarbons), heptane (n-heptane or a mixture of linear and branched C7 acyclic aliphatic hydrocarbons), octane (n-octane or a mixture of linear and branched C8 acyclic aliphatic hydrocarbons), or combinations thereof. Non-limiting examples of suitable cycloaliphatic hydrocarbons that may be used as the organic liquid medium and / or the organic reaction medium include cyclohexane and methylcyclohexane. Aromatic hydrocarbons that may be used as the organic liquid medium and / or the organic reaction medium include those having a C6 to C 10Suitable aromatic hydrocarbons that may be utilized as the organic liquid medium and / or the organic reaction medium include, but are not limited to, benzene, toluene, xylene (including ortho-xylene, meta-xylene, para-xylene, or mixtures thereof), ethylbenzene, or combinations thereof. Halogenated aliphatic hydrocarbons that may be utilized as the organic liquid medium and / or the organic reaction medium include C1-C 15 , C1~C 10 , or C1-C5 halogenated aliphatic hydrocarbons. Halogenated aliphatic hydrocarbons that may be used as the organic liquid medium and / or organic reaction medium may be cyclic or acyclic, and / or straight or branched chain, unless otherwise specified. Non-limiting examples of suitable halogenated aliphatic hydrocarbons that may be utilized as the organic liquid medium and / or organic reaction medium include methylene chloride, chloroform, carbon tetrachloride, dichloroethane, trichloroethane, and any combination thereof. Halogenated aromatic hydrocarbons that may be used as the organic liquid medium and / or organic reaction medium include C6-C 20 Or C6~C 10 Non-limiting examples of suitable halogenated aromatic hydrocarbons that may be used as the organic liquid medium and / or the organic reaction medium include chlorobenzene, dichlorobenzene, or combinations thereof.
[0099] The selection of the organic liquid medium and / or organic reaction medium may be made based on processing convenience. For example, isobutane may be selected to be compatible with the organic liquid medium and / or organic reaction medium used in the process using the product(s) of the process described herein (e.g., using the product to form a polymer in a subsequent processing step). In some aspects, the organic liquid medium and / or organic reaction medium may be selected to be easily separable from one or more of the oligomers in the oligomer product. In some aspects, an oligomer of the oligomer product may be utilized as the organic liquid medium and / or organic reaction medium. For example, if 1-hexene is the oligomer of the ethylene trimerization process or the ethylene trimerization and tetramerization process, 1-hexene may be selected as the organic liquid medium and / or organic reaction medium to reduce the need for separation. If 1-octene is the oligomer of the ethylene tetramerization process or the ethylene trimerization and tetramerization process, 1-octene may be selected as the organic liquid medium and / or organic reaction medium to reduce the need for separation.
[0100] In general, oligomeric products that may be produced using the processes described herein may be formed under conditions (or alternatively, the reaction zone may have any conditions) that 1) promote oligomeric product formation, 2) provide a desired rate of oligomeric product formation, 3) provide acceptable catalyst system productivity, 4) provide acceptable oligomer selectivity, and / or 5) provide acceptable polymer formation. In one aspect, the conditions under which oligomeric products may be formed may include (or alternatively, the reaction zone may have conditions that may include) one or more of catalyst system component ratios, chromium concentration, pressure, ethylene partial pressure, ethylene concentration, the presence of hydrogen (and its partial pressure and / or hydrogen:ethylene mass ratio), temperature, reaction time, single pass ethylene conversion, and / or catalyst system productivity. Catalyst system component ratios, chromium concentration, pressure, ethylene partial pressure, ethylene concentration, the presence of hydrogen (and its partial pressure and / or hydrogen:ethylene mass ratio), temperature, reaction time, single pass ethylene conversion, and catalyst system productivity are independently described herein and such independent descriptions may be used in any combination, without limitation, to describe the condition(s) under which oligomeric products may be formed and / or the condition(s) under which a reaction zone may be operated for any of the processes described herein.
[0101] In one embodiment, the oligomer product may be formed (or the reaction zone may be operated at) a minimum chromium molar ratio (Al:Cr molar ratio) of the organoaluminum aluminum:bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex (or alternatively, chromium salt) of 10:1, 50:1, 75:1, or 100:1, or alternatively or additionally, may be formed (or the reaction zone may be operated at) a maximum Al:Cr molar ratio of 5,000:1, 3,000:1, 2,000:1, 1,500:1, or 1,000:1. In one embodiment, the oligomer product may be formed (or the reaction zone may be operated at) an Al:Cr molar ratio ranging from any minimum Al:Cr molar ratio disclosed herein to any maximum Al:Cr molar ratio disclosed herein. In one non-limiting embodiment, the Al:Cr molar ratio can range from 10:1 to 5,000:1, 50:1 to 3,000:1, 75:1 to 2,000:1, 100:1 to 2,000:1, or 100:1 to 1,000:1. Other Al:Cr molar ratio ranges that can be utilized will be readily apparent to one of skill in the art in light of the present disclosure.
[0102] In one embodiment, the oligomer product is 1×10 -6 Cr equivalent / liter, 1 x 10 -5 Cr equivalents / liter, or 5 x 10 -4The reaction zone may be formed (or the reaction zone may be operated) at a minimum reaction zone chromium (or alternatively, chromium of the chromium salt) concentration (i.e., minimum chromium concentration) of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex of 1 Cr equivalent / liter, or alternatively or additionally at a maximum reaction zone chromium (or alternatively, chromium of the chromium salt) concentration (i.e., maximum chromium concentration) of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex of 1 Cr equivalent / liter, 0.5 Cr equivalent / liter, or 0.1 Cr equivalent / liter. In one embodiment, the oligomer product may be formed (or the reaction zone may be operated) at a reaction zone chromium concentration ranging from any minimum chromium concentration disclosed herein to any maximum chromium concentration disclosed herein. In one non-limiting embodiment, the reaction zone chromium concentration is greater than or equal to 1×10 -6 Cr equivalent / liter to 1Cr equivalent / liter, 1×10 -5 Cr equivalents / liter to 0.5Cr equivalents / liter, or 5 x 10 -4 Cr equivalents / liter to 0.1 Cr equivalents / liter. Other chromium concentration ranges that may be utilized will be readily apparent to one of ordinary skill in the art in light of the present disclosure.
[0103] In one embodiment, the oligomer product may be formed (or the reaction zone may be operated at) a minimum pressure of 5 psi (34.5 kPa), 50 psi (345 kPa), 100 psi (689 kPa), 150 psi (1.03 MPa), 250 psi (1.72 MPa), 500 psi (3.5 MPa), or 600 psi (4.1 MPa), or alternatively or additionally, may be formed (or the reaction zone may be operated at) a maximum pressure of 2,500 psi (17.2 MPa), 2,000 psi (13.8 MPa), 1,500 psi (10.3 MPa), 1250 psi (8.62 MPa), or 1000 psi (6.89 MPa). In one embodiment, the oligomer product can be formed (or the reaction zone can be operated at a pressure range) ranging from any minimum pressure disclosed herein to any maximum pressure disclosed herein. In some non-limiting embodiments, the oligomer product can be formed at a pressure range of 5 psi (34.5 kPa) to 2,500 psi (17.2 MPa), 5 psi (34.5 kPa) to 2,000 psi (13.8 MPa), 50 psi (345 kPa) to 2,000 psi (13.8 MPa), 100 psi (689 kPa) to 2,000 psi (13.8 MPa), 100 psi (689 kPa) to 1,500 psi ( The reaction zone may be formed (or operated at) a pressure of from 10.3 MPa, 150 psi (1.03 MPa) to 1500 psi (10.3 MPa), 250 psi (1.72 MPa) to 1250 psi (8.62 MPa), 500 psi (3.5 MPa) to 1250 psi (8.62 MPa), or 600 psi (4.1 MPa) to 1000 psi (6.89 MPa). Other pressure ranges that may be utilized will be readily apparent to one of skill in the art in light of the present disclosure.
[0104] In one embodiment, the oligomeric product may be formed (or the reaction zone may be operated at) a minimum ethylene partial pressure of 5 psi (34.5 kPa), 50 psi (345 kPa), 100 psi (689 kPa), 150 psi (1.03 MPa), 250 psi (1.72 MPa), or 500 psi (3.5 MPa), alternatively or additionally, may be formed (or the reaction zone may be operated at) a maximum ethylene partial pressure of 2,500 psi (17.2 MPa), 2,000 psi (13.8 MPa), 1,500 psi (10.3 MPa), 1250 psi (8.62 MPa), or 1000 psi (6.89 MPa). In one embodiment, the oligomeric product may be formed (or the reaction zone may be operated at) an ethylene partial pressure ranging from any minimum ethylene partial pressure disclosed herein to any maximum ethylene partial pressure disclosed herein. In some non-limiting embodiments, the oligomer product can be formed (or the reaction zone can be operated at) an ethylene partial pressure of from 5 psi (34.5 kPa) to 2,500 psi (17.2 MPa), from 5 psi (34.5 kPa) to 2,000 psi (13.8 MPa), from 50 psi (345 kPa) to 2,000 psi (13.8 MPa), from 100 psi (689 kPa) to 2,000 psi (13.8 MPa), from 100 psi (689 kPa) to 1,500 psi (10.3 MPa), from 150 psi (1.03 MPa) to 1250 psi (8.62 MPa), from 250 psi (1.72 MPa) to 1000 psi (6.89 MPa), or from 500 psi (3.5 MPa) to 1000 psi (6.89 MPa). Other ethylene partial pressure ranges will be readily apparent to one of ordinary skill in the art in light of the present disclosure.
[0105] In one embodiment, the oligomer product may be formed (or the reaction zone may be operated at) a minimum ethylene concentration of 4%, 10%, 25%, 35%, or 40% by weight based on the total weight in the reaction zone, alternatively or additionally, the oligomer product may be formed (or the reaction zone may be operated at) a maximum ethylene concentration of 70%, 65%, 60%, 55%, 50%, or 48% by weight based on the total weight in the reaction zone. In one embodiment, the oligomer product may be formed (or the reaction zone may be operated at) an ethylene concentration ranging from any minimum ethylene concentration disclosed herein to any maximum ethylene concentration disclosed herein. In some non-limiting embodiments, the oligomer product may be formed (or the reaction zone may be operated at an ethylene concentration within) the range of 4% to 70%, 4% to 65%, 10% to 60%, 25% to 60%, 25% to 55%, 35% to 50%, or 40% to 48% by weight based on the total weight in the reaction zone. Other ethylene concentration ranges that may be utilized will be readily apparent to one of skill in the art in light of the present disclosure.
[0106] In one embodiment, the oligomer product may be formed (or the reaction zone may be operated) at a minimum ethylene:chromium mass ratio of 50,000:1, 150,000:1, 250,000:1, or 400,000:1, alternatively or additionally at a maximum ethylene:chromium mass ratio of 5,000,000:1, 2,500,000:1, 1,500,000:1, or 1,000,000:1. In one embodiment, the oligomer product may be formed (or the reaction zone may be operated) at an ethylene:chromium mass ratio ranging from any minimum ethylene:chromium mass ratio disclosed herein to any maximum ethylene:chromium mass ratio disclosed herein. In some non-limiting embodiments, the oligomeric products may be formed (or the reaction zone may be operated at) ethylene:chromium mass ratios within the ranges of 50,000:1 to 5,000,000:1, 150,000:1 to 2,500,000:1, 250,000:1 to 1, 500,000:1, or 400,000:1 to 1,000,000:1. Other ethylene:chromium mass ratio ranges that may be utilized will be readily apparent to one of skill in the art in light of the present disclosure. In general, the ethylene:chromium mass ratio is based on the chromium in the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex (or alternatively, in the chromium salt).
[0107] In an embodiment where hydrogen is utilized, the oligomer product may be formed (or the reaction zone may be operated at) a minimum hydrogen partial pressure of 1 psi (6.9 kPa), 2 psi (14 kPa), 5 psi (34 kPa), 10 psi (69 kPa), or 15 psi (103 kPa), alternatively or additionally, a maximum hydrogen partial pressure of 200 psi (1.4 MPa), 150 psi (1.03 MPa), 100 psi (689 kPa), 75 psi (517 kPa), or 50 psi (345 kPa). In an embodiment, the oligomer product may be formed (or the reaction zone may be operated at) a hydrogen partial pressure ranging from any minimum hydrogen partial pressure disclosed herein to any maximum hydrogen partial pressure disclosed herein. In some non-limiting embodiments in which hydrogen is utilized, oligomeric products may be formed (or the reaction zone may be operated at) hydrogen partial pressures of from 1 psi (6.9 kPa) to 200 psi (1.4 MPa), from 2 psi (14 kPa) to 150 psi (1.03 MPa), from 5 psi (34 kPa) to 100 psi (689 kPa), from 10 psi (69 kPa) to 75 psi (517 kPa), or from 15 psi (103 kPa) to 50 psi (345 kPa). Other hydrogen partial pressure ranges that may be utilized will be readily apparent to one of skill in the art in light of this disclosure.
[0108] In one embodiment where hydrogen is utilized, oligomeric products may be formed (or the reaction zone may be operated at) a minimum hydrogen:ethylene mass ratio of (0.05 g hydrogen) / (kg ethylene), (0.1 g hydrogen) / (kg ethylene), (0.25 g hydrogen) / (kg ethylene), (0.4 g hydrogen) / (kg ethylene), or (0.5 g hydrogen) / (kg ethylene), or alternatively or additionally, may be formed (or the reaction zone may be operated at) a maximum hydrogen:ethylene mass ratio of (5 g hydrogen) / (kg ethylene), (3 g hydrogen) / (kg ethylene), (2.5 g hydrogen) / (kg ethylene), (2 g hydrogen) / (kg ethylene), or (1.5 g hydrogen) / (kg ethylene). In one embodiment, oligomeric products may be formed (or the reaction zone may be operated at) hydrogen:ethylene mass ratios ranging from any minimum hydrogen:ethylene mass ratio disclosed herein to any maximum hydrogen:ethylene mass ratio disclosed herein. In some non-limiting embodiments, oligomeric products may be formed (or the reaction zone may be operated at) hydrogen:ethylene mass ratios of from (0.05 g hydrogen) / (kg ethylene) to (5 g hydrogen) / (kg ethylene), from (0.1 g hydrogen) / (kg ethylene) to (5 g hydrogen) / (kg ethylene), from (0.25 g hydrogen) / (kg ethylene) to (4 g hydrogen) / (kg ethylene), from (0.4 g hydrogen) / (kg ethylene) to (3 g hydrogen) / (kg ethylene), from (0.4 g hydrogen) / (kg ethylene) to (2.5 g hydrogen) / (kg ethylene), from (0.4 g hydrogen) / (kg ethylene) to (2 g hydrogen) / (kg ethylene), from (0.5 g hydrogen) / (kg ethylene) to (2 g hydrogen) / (kg ethylene), or from (0.5 g hydrogen) / (kg ethylene) to (1.5 g hydrogen) / (kg ethylene). Other hydrogen:ethylene mass ratio ranges that may be utilized will be readily apparent to those of skill in the art in light of the present disclosure.
[0109] In one embodiment, the oligomeric product may be formed (or the reaction zone may be operated at a minimum hydrogen:chromium mass ratio of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex (or alternatively, the chromium salt) (minimum hydrogen:chromium mass ratio) of 1:1, 50:1, 100:1, or 200:1, or alternatively or additionally, may be formed (or the reaction zone may be operated at a maximum hydrogen:chromium mass ratio of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex (or alternatively, the chromium salt) (maximum hydrogen:chromium mass ratio) of 100,000:1, 50,000:1, 10,000:1, or 3,000:1. In one embodiment, the oligomer product may be formed (or the reaction zone may be operated at) a hydrogen:chromium mass ratio (hydrogen:chromium mass ratio) of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex (or alternatively, chromium salt) ranging from any minimum hydrogen:chromium mass ratio disclosed herein to any maximum hydrogen:chromium mass ratio disclosed herein. In some non-limiting embodiments, the oligomer product may be formed (or the reaction zone may be operated at) a hydrogen:chromium mass ratio within the range of 1:1 to 100,000:1, 50:1 to 50,000:1, 100:1 to 10,000:1, or 200:1 to 3,000:1. Other hydrogen:chromium mass ratio ranges that may be utilized will be readily apparent to one of skill in the art in light of the present disclosure. Generally, the hydrogen:chromium mass ratio is based on the chromium in the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex (or alternatively, in the chromium salt).
[0110] In one embodiment, the oligomer product may be formed (or the reaction zone may be operated at) a minimum temperature of 0° C., 25° C., 40° C., or 50° C., alternatively or additionally, the oligomer product may be formed (or the reaction zone may be operated at) a maximum temperature of 200° C., 150° C., 100° C., or 90° C. In one embodiment, the oligomer product may be formed (or the reaction zone may be operated at) a temperature ranging from any minimum temperature disclosed herein to any maximum temperature disclosed herein. In some non-limiting embodiments, the oligomer product may be formed (or the reaction zone may be operated at) a temperature of 0° C. to 200° C., 25° C. to 150° C., 40° C. to 100° C., 50° C. to 100° C., or 50° C. to 90° C. Other temperature ranges that may be utilized will be readily apparent to one of skill in the art in light of the present disclosure.
[0111] The reaction time (or residence time or average residence time) in the reaction zone can include any time that can provide a desired amount of oligomer product, alternatively any reaction time (or residence time) that can provide a desired catalyst system productivity, alternatively any reaction time (or residence time or average residence time) that can provide a desired ethylene conversion. With respect to the formation of oligomer products, the oligomer products can be formed over a period of time (or average residence time) that can provide a desired amount of olefin or polymer product, provide a desired catalyst system productivity, and / or provide a desired monomer conversion. In some embodiments, the reaction time (or residence time or average residence time) can range from 1 minute to 5 hours, alternatively from 5 minutes to 2.5 hours, alternatively from 10 minutes to 2 hours, or alternatively from 15 minutes to 1.5 hours. In some embodiments (continuous process embodiments), the reaction time (or residence time or average residence time), which may be described as the average reaction time (or average residence time), may range from 1 minute to 5 hours, alternatively, from 5 minutes to 2.5 hours, alternatively, from 10 minutes to 2 hours, or alternatively, from 15 minutes to 1.5 hours.
[0112] In one embodiment, the processes described herein may have an ethylene conversion of at least 30%, 35%, 40%, or 45%. In another embodiment, the ethylene conversion may be a single pass conversion of at least 30%, 35%, 40%, or 45%.
[0113] In an embodiment, the processes described herein may have a catalyst system productivity of greater than 10,000, 50,000, 100,000, 150,000, 200,000, 300,000, or 400,000 grams of (C6+C8) per gram of chromium (g(C6+C8) / gCr).
[0114] Depending on the catalyst system utilized, the process described herein may be an ethylene oligomerization process, an ethylene trimerization process, an ethylene tetramerization process, or an ethylene trimerization and tetramerization process, alternatively an ethylene oligomerization process, alternatively an ethylene trimerization process, alternatively an ethylene tetramerization process, or alternatively an ethylene trimerization and tetramerization process. In an ethylene trimerization embodiment, the oligomer product may comprise at least 70 wt.% hexene, at least 75 wt.% hexene, at least 80 wt.% hexene, at least 85 wt.% hexene, or at least 90 wt.% hexene based on the weight of the oligomer product. In some ethylene trimerization embodiments, the oligomer product may comprise 70 wt.% to 99.8 wt.% hexene, 75 wt.% to 99.7 wt.% hexene, or 80 wt.% to 99.6 wt.% hexene based on the weight of the oligomer product. In ethylene tetramerization embodiments, the oligomer product may comprise at least 70 wt.% octene, at least 75 wt.% octene, at least 80 wt.% octene, at least 85 wt.% octene, or at least 90 wt.% octene based on the weight of the oligomer product. In some ethylene tetramerization embodiments, the oligomer product may comprise 70 wt.% to 99.8 wt.% octene, 75 wt.% to 99.7 wt.% octene, or 80 wt.% to 99.6 wt.% octene based on the weight of the oligomer product. In ethylene trimerization and tetramerization embodiments, the oligomer product may comprise at least 70 wt.% hexene and octene, at least 75 wt.% hexene and octene, at least 80 wt.% hexene and octene, at least 85 wt.% hexene and octene, or at least 90 wt.% hexene and octene based on the weight of the oligomer product.In some ethylene trimerization and tetramerization embodiments, the oligomer product can contain 70 wt.% to 99.8 wt.% hexenes and octene, 75 wt.% to 99.7 wt.% hexenes and octene, or 80 wt.% to 99.6 wt.% hexenes and octene, based on the weight of the oligomer product.
[0115] In an ethylene oligomerization embodiment, an ethylene trimerization embodiment, or an ethylene trimerization and tetramerization embodiment, the ethylene trimer may comprise at least 90 wt.% 1-hexene, alternatively at least 92.5 wt.% 1-hexene, alternatively at least 95 wt.% 1-hexene, alternatively at least 97 wt.% 1-hexene, or alternatively at least 98 wt.% 1-hexene, by weight of the ethylene trimer. In other ethylene oligomerization embodiments, ethylene trimerization embodiments, or ethylene trimerization and tetramerization embodiments, the ethylene trimer may comprise 85 wt.% to 99.9 wt.% 1-hexene, alternatively 87.5 wt.% to 99.9 wt.% 1-hexene, alternatively 90 wt.% to 99.9 wt.% 1-hexene, alternatively 92.5 wt.% to 99.9 wt.% 1-hexene, alternatively 95 wt.% to 99.9 wt.% 1-hexene, alternatively 97 wt.% to 99.9 wt.% 1-hexene, or alternatively 98 wt.% to 99.9 wt.% 1-hexene, by weight of the ethylene trimer.
[0116] In an ethylene oligomerization embodiment, an ethylene tetramerization embodiment, or an ethylene trimerization and tetramerization embodiment, the ethylene tetramer may comprise at least 85 wt.% 1-octene, alternatively at least 90 wt.% 1-octene, alternatively at least 92.5 wt.% 1-octene, alternatively at least 95 wt.% 1-octene, alternatively at least 97 wt.% 1-octene, or alternatively at least 98 wt.% 1-octene, by weight of the ethylene tetramer. In other ethylene oligomerization embodiments, ethylene tetramerization embodiments, or ethylene trimerization and tetramerization embodiments, the ethylene tetramer may comprise, by weight of the ethylene tetramer, 85 wt.% to 99.9 wt.% 1-octene, alternatively, 90 wt.% to 99.9 wt.% 1-octene, alternatively, 92.5 wt.% to 99.9 wt.% 1-octene, alternatively, 95 wt.% to 99.9 wt.% 1-octene, alternatively, 97 wt.% to 99.9 wt.% 1-octene, or alternatively, 98 wt.% to 99.9 wt.% 1-octene.
[0117] In some embodiments, the processes described herein utilizing a bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex (or alternatively, a bicyclic 2-[(phosphinyl)aminyl] cyclic imine and a chromium salt) can produce an oligomeric product comprising a mixture of C8 and C6 olefin products, and the mass ratio of C8 olefin products to C6 olefin products can be at least 0.5:1, at least 1:1, at least 1.5:1, or at least 1.75:1. EXAMPLES
[0118] methodology Accurate density functional theory (DFT), solvation methods, and quantum mechanics tools have been developed that may allow prediction of products from molecular catalysts. In one field, there is interest in being able to predict the relative amounts of hexene and / or octene produced by an ethylene trimerization and / or tetramerization catalyst system. In order to be able to use computational methods to predict the relative amounts of hexene and / or octene produced by a particular ethylene trimerization and / or tetramerization catalyst, a plausible mechanism is needed that can demonstrate hexene and / or octene selectivity.Although not bound by theory, i) Britovsek, GJPand McGuinness,DSChem.Eur.J.2016,22,16891-16896, ii)Britovsek,GJP;McGuinness,DS;Tomov,AKCatal.Sci.Technol.2016,6,8234-8241,iii)Hossain,MA;Kim,HS;Houk,KNCheong,M.Bull.Korean Chem.Soc.2014,35,2835-2838, iv)Gong,M.;Liu,Z.;Li,Y.;Ma,Y.;Sun,Q.;Zhang,J.;Liu,B.Organometallics 2016,35,972-981, v) Yang, Y.; Liu, Z.; Cheng, R.; He, X.; Liu, B. Organometallics 2014,33,2599-2607, vi)Qi,Y.;Zhong,L.;Liu,Z.;Qiu,P.;Cheng,R.;He,X.;Vanderbilt,J.;Liu,B.Organometallics 2010,29,1588-1602, vii) Budzelaar,PHMCan.J.Chem.2009,87,832-837,viii)Bhaduri,S.;Mukhopadhyay,S.;Kulkarni,SAJOrganomet.Chem.2009,694,1297-1307,and ix)van Using computational and experimental studies in Rensburg, WJ; Grove, C.; Steynberg, JP; Stark, KB; Huyser, JJ; Steynberg, PJOrganometallics 2004, 23, 1207-1222 and experimental studies in Bartlett, SA; Moulin, J.; Tromp, M.; Reid, G.; Dent, AJ; Cibin, G.; McGuinness, DS; Evans, J. ACS Catal. 2014, 4, 4201-4204, we developed Scheme 1 as a plausible catalytic mechanism for ethylene trimerization and / or tetramerization. [ka] In Scheme 1, low-valent Cr-ethylene coordinated species A can be generated by pre-catalytic activation in the presence of ethylene. Oxidative C-C bond coupling of two ethylene units can form chromacyclopentane B, which can then be coordinated with another ethylene to form chromacyclopentane ethylene coordinated species C, followed by rearrangement insertion of ethylene to give chromacycloheptane intermediate D. Intermediate D is a common intermediate in the mechanistic pathway where the hexene and octene formation mechanisms can diverge. Hexene can be produced from chromacycloheptane intermediate D by β-hydrogen transfer via transition state TS1, resulting in the formation of 1-hexene and reduced Cr species, which can then form low-valent Cr-ethylene coordinated species A again in the presence of ethylene. i) ethylene coordination to form the ethylene-coordinated species E; ii) ethylene rearrangement insertion via transition state TS2 to form the chromacyclononane species F; and iii) octene can be produced from the chromacycloheptane intermediate D by β-hydrogen transfer within the chromacyclononane species F to give 1-octene and a reduced Cr species, which can then re-form the low-valent Cr-ethylene-coordinated species A in the presence of ethylene. This two-transition state model assumes a dynamic equilibrium (often known as the Curtin-Hammett state) in which TS1 and TS2 form the common chromacycloheptane intermediate D, as well as a rapid equilibrium of possible intermediates leading to TS1 and TS2. Through this mechanism, selectivity can arise from the competition between β-hydrogen transfer of transition state TS1 and rearrangement insertion of ethylene from intermediate D via transition state TS2.
[0119] Without being bound by theory, the mechanism of Scheme 1 can then be applied to predictive methods to determine the previously unknown N 2 This makes it possible to predict the relative amounts of hexene and / or octene for N-phosphinyl amidine chromium salt complexes (e.g., the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complexes disclosed herein). 2Density functional theory calculations were applied to the -phosphinyl amidine chromium salt complexes to obtain a correlation between the density functional theory calculations and the experimentally observed amounts of hexene and / or octene. This correlation was then used to predict the amount of hexene and / or octene produced by the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes disclosed herein.
[0120] Without wishing to be bound by theory, Scheme 2 and Scheme 3 show the critical competitive and selective reaction coordinate pathways for the production of hexene and octene using bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes having structure BPACICr I or structure BPACICr II, respectively. These schemes include the respective generic bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes CrCH1, the respective generic bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes CrCH2, the respective generic bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes hexene transition state TS C6, and the respective generic bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes octene transition state TS C8. Thus, for a catalyst system based on a general bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex having the structure BPACICr I or the structure BPACICr II, the Gibbs free energy difference ΔΔG between 1) the difference in the Gibbs free energy of the respective general bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium chromacycloheptane complex CrCH1 and the respective general bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex hexene transition state TS C6 and 2) the difference in the Gibbs free energy of the respective general bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium chromacycloheptane complex CrCH2 and the respective general bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex octene transition state TS C8 ‡can be used in predictive correlation methods to predict the relative amounts of hexene and / or octene produced by the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complexes of structure BPACICr I or BPACICr II. Furthermore, without being bound by theory, the relative amounts of hexene and / or octene produced by the respective general bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complexes of structure CrCH1 and the general N 2 The 2-phosphinylamidine chromium chromacycloheptane complexes CrCH2 are carbon-carbon chromacycloheptane rotamers, and the energy barrier for their interconversion is expected to be low. Therefore, the Gibbs free energy difference (ΔΔG in Scheme 2) between each of the general bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes hexene transition state TS C6 and each of the general bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complexes octene transition state TS C8 can be calculated by the following equation. ‡ ) to calculate the Gibbs free energy difference ΔΔG ‡ In this way, we can simplify the calculation of the Gibbs free energy difference ΔΔG ‡ was correlated with the experimentally observed amounts of hexene and / or octene produced by experimentally tested bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complexes. [ka] [ka]
[0121] Density functional theory calculations Density functional theory calculations (specifically, the unrestricted UM06L / Def2-TZVP / / UM06 / 6-31G(d,p) (LANL2DZ) theory) in combination with the SMD implicit solvent model for cyclohexane (as implemented in Marenich, AV; Cramer, CJ; Truhlar, DG, J. Phys. Chem. B. 2009, 113, 6378-6396) were used to determine the cationic bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex hexene transition state TS C6 (hereafter referred to as the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex hexene transition state TS C6) and the cationic bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex octene transition state TS The Gibbs free energy of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex hexene transition state TS C8 (hereafter referred to as bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex hexene transition state TS C8) was calculated for each bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex. Next, the Gibbs free energy difference ΔΔG between the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex hexene transition state TS C6 and the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex octene transition state TS C8 was calculated as ‡ was calculated for each bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex. Calculations of the Gibbs free energy of the cationic bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex transition state TS C6 (and other transition state energies used herein) and the cationic bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex octene transition state TS C8 (and other transition state energies used herein) were performed without considering the effect of the equilibrium anion.
[0122] Density functional theory calculations were performed using Gaussian09 (Frisch, MJ et al. Gaussian09 TM The experiment was performed using Gaussian,Inc. (Revision B.01, Gaussian,Inc.: Wallingford, CT, USA, 2009).
[0123] Bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex hexene transition state TS C6 (3-40 conformations depending on the exact ligand) and bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex octene transition state TS Geometries to describe each degree of freedom and each spin state of C8 (3-40 conformations depending on the exact ligand) were calculated for each bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex using the pseudopotential LANL2DZ basis set (integrated in Gaussian09™, revision B.01) for chromium and the unrestricted approximation of the local Minnesota06 density functional theory 6-31G(d,p) basis set (i.e., UM06 / 6-31G(d,p) basis set) for all other atoms in the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt transition state. Transition state structures with a full set of force constants were calculated to confirm a single negative vibrational frequency corresponding to the reaction coordinate. Additionally, ground state structure vibrational frequencies were calculated and analyzed to correspond to second order energy derivatives (i.e., force constants) to confirm the local minimum energy structures. Additionally, zero-point energies (ΔE ZPE(小) ), vibrational energy, rotational energy, and translational energy (ΔU vib(小) , ΔU rot(小) , ΔU trans(小) ), and the vibrational, rotational, and translational entropy (ΔS vib(小) , ΔS rot(小) , ΔS trans(小) ) was obtained and used to calculate the Gibbs free energy of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex hexene transition state TS C6 and the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex octene transition state TS C8.
[0124] The solvation geometries for the lowest energy bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex hexene transition state TS C6 conformation and the lowest energy bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex octene transition state TS C8 conformation, along with any conformations with energies relatively close to the lowest energy bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex hexene transition state TS C6 conformation and the lowest energy bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex octene transition state TS C8 conformation, were calculated using the continuum model (SMD) parameterized and implemented in Gaussian09 for cyclohexane. The transition state structure with the full set of force constants was calculated to confirm a single negative vibrational frequency corresponding to the reaction coordinate. Furthermore, the ground state structural vibrational frequencies were calculated to correspond to the second energy derivatives (i.e., force constants) and analyzed to confirm the local minimum energy structures.
[0125] Next, the electron kinetic energy, potential energy, and internuclear repulsion energy (E (大) ) as well as the standard state solvation free energy change (ΔG solv(大) ) were calculated using the unrestricted approximation of the local Minnesota06 density functional theory Def2-TZVP basis set UM06L / Def2-TZVP (downloaded from https: / / bse.pnl.gov / bse / portal on 2016 / 01 / 01) to obtain accurate spin-state energies and accurate calculations for weak dispersion forces.
[0126] Next, E (大) +ΔE ZPE(小) +ΔU vib(小) +ΔU rot(小) +ΔU trans(小) +nRT-TΔS vib(小) -TΔSrot(小) -TΔS trans(小) +ΔG solv(大) The Gibbs free energies of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex hexene transition state TS C6 and the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex octene transition state TS C8 were calculated using the following equation (where R is the ideal gas constant and T is the temperature (298 K was used for these calculations): ‡ was calculated as the Gibbs free energy of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex hexene transition state TS C6 minus the Gibbs free energy of the bicyclic 2-[(phosphinyl)aminyl] cyclic imine chromium salt complex octene transition state TS C8.
[0127] Table 1 shows the N 2 Experimental data were determined using chromium complexes with -phosphinyl amidine ligands. 2 -phosphinyl amidine chromium salt complexes (NPA1 to NPA5) (see the ethylene oligomerization example) 2 -Phosphinyl amidine chromium salt complex hexene transition state TS C6 and N 2 Calculated ΔΔG between the octene transition state TS C8 and the phosphinyl amidine chromium salt complex ‡ Table 1 provides ΔΔG values for bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complexes using ligands having structures BPACI1, BPACI2, BPACI3, and BPACI4. ‡ and further provides predictions of product distribution.
[0128] Ethylene Oligomerization Example A 1 L stainless steel autoclave reactor was dried under vacuum at 110 °C for at least 8 h before use. The reactor was then cooled to 50 °C. In a dry box, N 2 A mixture of 10-phosphinyl amidine chromium complex (0.009-0.010 mmol), ethylbenzene (2.00 g), MMAO-3A (400-800 equiv.), Al (7 wt.% Al solution in heptane), and internal standard (n-nonane, 1.00 g) was placed in a 20 mL glass vial. This solution was then added to a 0.5 L glass vessel containing cyclohexane (400 mL). This combined solution was removed from the dry box and placed in a 1 L stainless steel autoclave reactor under static vacuum. The reactor was then heated to 5 °C below the reaction temperature and the reactor was charged with hydrogen. The reactor was then charged with ethylene as needed to maintain the desired operating pressure. After 30 min, water cooling was applied to the 1 L stainless steel autoclave reactor to terminate the ethylene oligomerization reaction. Once the reactor temperature reached 35 °C, the unreacted ethylene and hydrogen gas were vented to the atmosphere. Liquid samples of the contents of the 1 L stainless steel autoclave reactor were then collected at room temperature and analyzed by gas chromatography. The reactor solids were collected by filtering the reaction and washing the reactor walls and cooling coils. Table 1 shows the N 2 For each of the chromium salt complexes of phosphinyl amidine ligands 1-5, the weight percent of trimer (1-hexene) and tetramer (1-octene) found in the oligomer products (as a percentage of the total trimers and tetramers produced) is reported. [Table 2-1] [Table 2-2]
[0129] ΔΔG ‡ and correlation with C6 / C8 mass ratio Experimentally evaluated N 2 Calculated ΔΔG for chromium salt complexes of the -phosphinyl amidine ligands NPA1 to NPA5‡ The five N 2 When chromium salt complexes of N-phosphinyl amidine ligands were utilized in catalyst systems for ethylene oligomerization (see the ethylene oligomerization examples provided herein), it was found to provide a good linear correlation with the natural logarithm of the C6:C8 mass ratio (ln(C6 mass / C8 mass) (or alternatively ln(C6 / C8)). FIG. 1 shows the five N-phosphinyl amidine ligands in Table 1. 2 Calculated ΔΔG for chromium salt complexes of -phosphinyl amidine ligands ‡ A graph of ln(C6 / C8) vs. the correlation coefficient R of the least squares fitting line of this data is provided. 2 is 0.9744, which means that ΔΔG ‡ It is shown that there is a good correlation between the experimentally observed masses of hexene and octene. ‡ The versus ln(C6 / C8) trend line was used to calculate ln(C6 / C8) for chromium salt complexes of bicyclic 2-[(phosphinyl)aminyl]cyclic imine ligands having structures BPACI1-BPACI4. The linear correlation given in Figure 1 was then used to determine ln(C6 / C8), and the corresponding mass % of C6 and mass % of C8 are given in Table 1.
[0130] N 2 -Synthesis of phosphinyl amidine ligands N 2 Synthesis of the -phosphinyl amidine ligands (NPA1-NPA5), as well as potential synthesis of the bicyclic 2-[(phosphinyl)aminyl]cyclic imine ligands of the present disclosure (e.g., BPACI1, BPACI2, BPACI3, and BPACI4), can be carried out using the general synthetic procedures provided in U.S. Patent Application No. 15 / 166,991 and U.S. Patent Application No. 15 / 171,170, which are incorporated herein by reference in their entireties.
[0131] Additional Disclosures Therefore, the scope of protection is not limited by the above description, but only by the claims that follow, including all equivalents of the subject matter of the claims. Any and all claims are incorporated herein as aspects of the disclosure. Thus, the claims are further explanation and join the detailed description of the disclosure. The disclosures of all patents, patent applications, and publications cited herein are incorporated herein by reference.
[0132] Statement 1 i) (a) Structure BPACICr I or Structure BPACICr II [ka] Bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complexes having the formula or (b) a chromium salt and structure BPACI I or structure BPACI II. [ka] and a bicyclic 2-[(phosphinyl)aminyl]cyclic imine having the formula In the formula, R 21 , R 22 , R 23 , and R 24 are independently hydrogen or C1-C 30 is an organyl group, L 1 , L 2 , and L 3 However, independently, C1~C 30 is a hydrocarbylene group, R 4 and R 5 However, independently, C1~C 30 is an organyl group, R 4 and R 5 optionally taken together to form a ring or ring system containing a phosphorus atom, L 45 It forms L 45 C1~C 30 Organylene group, CrX pa bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex, or a bicyclic 2-[(phosphinyl)aminyl]cyclic imine, wherein X is a chromium salt, X is a monoanion, and p is an integer of 2 to 6; and ii) an organoaluminum compound.
[0133] Statement 2 2. The catalyst system of claim 1, wherein the organoaluminum compound comprises an aluminoxane.
[0134] Statement 3 The catalyst system of statement 2, wherein the aluminoxane comprises methylaluminoxane (MAO), modified methylaluminoxane, ethylaluminoxane, n-propylaluminoxane, iso-propylaluminoxane, n-butylaluminoxane, sec-butylaluminoxane, iso-butylaluminoxane, t-butylaluminoxane, 1-pentylaluminoxane, 2-pentylaluminoxane, 3-pentylaluminoxane, iso-pentylaluminoxane, neopentylaluminoxane, or a mixture thereof.
[0135] Statement 4 4. The catalyst system according to any one of statements 1 to 3, wherein the catalyst system has a molar ratio of aluminum of the organoaluminum compound to chromium of the chromium salt or chromium of the 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex in the range of 10:1 to 5,000:1.
[0136] Statement 5 a) i) ethylene and ii) (a)(i) structure BPACICr I or structure BPACICr II [ka] Bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complexes having the formula or (ii) a chromium salt and a compound of structure BPACI I or structure BPACI II. [ka] and a bicyclic 2-[(phosphinyl)aminyl]cyclic imine having the formula In the formula, R 21 , R 22 , R 23 , and R 24 are independently hydrogen or C1-C 30 is an organyl group, L 1 , L 2 , and L 3 However, independently, C1~C 30 is a hydrocarbylene group, R 4 and R 5 However, independently, C1~C 30 is an organyl group, R 4 and R 5 optionally taken together to form a ring or ring system containing a phosphorus atom, L 45 It forms L 45 C1~C 30 Organylene group, CrX p is a chromium salt, X is a monoanion, and p is an integer from 2 to 6, or the chromium salt and the bicyclic 2-[(phosphinyl)aminyl]cyclic imine, (b) a catalyst system comprising an organoaluminum compound, and (iii) optionally an organic reaction medium; and b) forming oligomeric products in a reaction zone.
[0137] Statement 6 The process of statement 5, wherein the reaction zone has any temperature disclosed herein (e.g., within the range of at least 0°C, 25°C, 40°C, or 50°C, 0°C to 200°C, 25°C to 150°C, 40°C to 100°C, 50°C to 100°C, or 50°C to 90°C, among others).
[0138] Statement 7 7. The process of any one of statements 5 or 6, wherein the reaction zone has any ethylene partial pressure disclosed herein (e.g., within the range of at least 5 psi (34.5 kPa), 50 psi (345 kPa), 250 psi (1.72 MPa), or 500 psi (3.5 MPa), 5 psi (34.5 kPa) to 2,500 psi (17.2 MPa), 5 psi (34.5 kPa) to 2,000 psi (13.8 MPa), 100 psi (689 kPa) to 2,000 psi (13.8 MPa), 500 psi (3.5 MPa) to 1500 psi (10.3 MPa), 150 psi (1.03 MPa) to 1250 psi (8.62 MPa), or 250 psi (1.72 MPa) to 1000 psi (6.89 MPa), among others).
[0139] Statement 8 The process of any one of statements 5-7, wherein the reaction zone has any ethylene:chromium mass ratio disclosed herein (e.g., within the ranges of 50,000:1, 150,000:1, 250,000:1, or 400,000:1, 50,000:1 to 5,000,000:1, 150,000:1 to 2,500,000:1, 250,000:1 to 1,500,000:1, or 400,000:1 to 1,000,000:1, among others).
[0140] Statement 9 The process of statement 8, wherein the organoaluminum compound comprises or consists essentially of an aluminoxane.
[0141] Statement 10 The process of statement 9, wherein the aluminoxane comprises or consists essentially of methylaluminoxane (MAO), modified methylaluminoxane, ethylaluminoxane, n-propylaluminoxane, iso-propylaluminoxane, n-butylaluminoxane, sec-butylaluminoxane, iso-butylaluminoxane, t-butylaluminoxane, 1-pentylaluminoxane, 2-pentylaluminoxane, 3-pentylaluminoxane, iso-pentylaluminoxane, neopentylaluminoxane, or mixtures thereof.
[0142] Statement 11 The process of any one of statements 5-10, wherein the reaction zone has aluminum of the organoaluminum compound and chromium of the 2-[(phosphinyl)aminyl]cyclicimine chromium salt complex in any molar ratio disclosed herein (e.g., within the ranges of at least 10:1, 50:1, 75:1, or 100:1, 10:1 to 5,000:1, 50:1 to 3,000:1, 50:1 to 3,000:1, 75:1 to 2,000:1, 100:1 to 2,000:1, or 100:1 to 1,000:1, among others).
[0143] Statement 12 The reaction zone is configured to react chromium from the 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex at any concentration disclosed herein (e.g., at least 1×10 -6 Cr equivalent / liter, 1 x 10 -5 Cr equivalents / liter, or 5 x 10 -4 Cr equivalent / liter, 1 x 10 -6 Cr equivalent / liter to 1Cr equivalent / liter, 1×10 -5 Cr equivalent / liter ~5×10 -1 Cr equivalent / liter, 5 x 10 -4 Cr equivalent / liter ~ 1 x 10 -1 The process according to any one of statements 5 to 11, wherein the Cr equivalent / liter range is 0.01 to 0.15.
[0144] Statement 13 The process of any one of statements 5-12, wherein the reaction zone has any ethylene concentration disclosed herein based on the total mass in the reaction zone (e.g., in the range of at least 4 mass%, 10 mass%, 25 mass%, 35 mass%, or 40 mass%, 4 mass% to 70 mass%, 4 mass% to 60 mass%, 10 mass% to 60 mass%, 25 mass% to 55 mass%, 35 mass% to 50 mass%, or 40 mass% to 48 mass%, among others).
[0145] Statement 14 The process of any one of statements 5-13, wherein the process further comprises contacting hydrogen with the ethylene, the catalyst system, and the optional organic reaction medium, and the reaction zone has any hydrogen partial pressure disclosed herein (e.g., at least 1 psi (6.9 kPa), 2 psi (14 kPa), 5 psi (34 kPa), 10 psi (69 kPa), or 15 psi (103 kPa), from 1 psi (6.9 kPa) to 200 psi (1.4 MPa), from 5 psi (34 kPa) to 150 psi (1.03 MPa), from 10 psi (69 kPa) to 100 psi (689 kPa), or from 15 psi (100 kPa) to 75 psig (517 kPa), among others).
[0146] Statement 15 The process further comprises contacting hydrogen with the ethylene, the catalyst system, and the optional organic reaction medium, and wherein the reaction zone is at least one of the hydrogen:ethylene mass ratios disclosed herein (e.g., at least one of ... 14. The process of any one of statements 5 to 13, wherein the hydrogen permeability is within the range of (kg ethylene) to (5 g hydrogen) / (kg ethylene), (0.25 g hydrogen) / (kg ethylene) to (4 g hydrogen) / (kg ethylene), (0.4 g hydrogen) / (kg ethylene) to (3 g hydrogen) / (kg ethylene), (0.4 g hydrogen) / (kg ethylene) to (2.5 g hydrogen) / (kg ethylene), (0.4 g hydrogen) / (kg ethylene) to (2 g hydrogen) / (kg ethylene), or (0.5 g hydrogen) / (kg ethylene) to (2 g hydrogen) / (kg ethylene).
[0147] Statement 16 16. The process of statement 14 or 15, wherein the process further comprises contacting hydrogen with the ethylene, the catalyst system, and the optional organic reaction medium, and wherein the reaction zone has any hydrogen:chromium mass ratio disclosed herein (e.g., within the ranges of at least 1:1, 50:1, 100:1, or 200:1, 1:1 to 100,000:1, 50:1 to 50,000:1, 100:1 to 10,000:1, or 200:1 to 3,000:1, among others).
[0148] Statement 17 17. The process of any one of statements 5-16, wherein the liquid oligomeric product comprises any amount of hexene, octene, or any combination thereof disclosed herein.
[0149] Statement 18 The process of any one of statements 5-17, wherein the ethylene trimer has any 1-hexene content disclosed herein (e.g., at least 90 wt.%, 92.5 wt.%, 95 wt.%, 97 wt.%, or 98 wt.% 1-hexene, 85 wt.% to 99.9 wt.%, 87.5 wt.% to 99.9 wt.%, 90 wt.% to 99.9 wt.%, 92.5 wt.% to 99.9 wt.%, 95 wt.% to 99.9 wt.%, 97 wt.% to 99.9 wt.%, or 98 wt.% to 99.9 wt.% 1-hexene, among others).
[0150] Statement 19 The process of any one of statements 5-18, wherein the ethylene tetramer has any 1-octene content disclosed herein (e.g., 90 wt.%, 92.5 wt.%, at least 95 wt.%, at least 97 wt.% 1-octene, or 98 wt.% 1-octene, 90 wt.% to 99.9 wt.%, 92.5 wt.% to 99.9 wt.%, 95 wt.% to 99.9 wt.%, 97 wt.% to 99.9 wt.%, or 98 wt.% to 99.9 wt.% 1-octene, among others).
[0151] Statement 20 The process of any one of statements 5-20, wherein the oligomeric product has any C8 / C6 ratio disclosed herein (e.g., at least 0.5:1, 0.75:1, 1:1, 1.5:, or 2:1, or alternatively, from 0.5:1 to 50:1, from 0.75:1 to 45:1, from 1.5:1 to 40:1, or from 2:1 to 35:1).
[0152] Statement 21 L 1 The catalyst system according to any one of statements 1 to 4 or the process according to any one of statements 5 to 20, wherein is a methylene group, an eth-1,2-ylene group, or a prop-1,3-ylene group.
[0153] Statement 22 L 2A catalyst system according to any one of statements 1 to 4 or 21, or a process according to any one of statements 5 to 21, wherein
[0154] Statement 23 L 3 A catalyst system according to any one of statements 1 to 4 or 21 to 22, or a process according to any one of statements 5 to 22, wherein is a methylene group, an eth-1,2-ylene group, or a prop-1,3-ylene group.
[0155] Statement 24 R 21 , R 22 , R 23 , and R 24 are independently hydrogen or any C1-C substituted or unsubstituted functional groups as described herein. 30 A catalyst system according to any one of statements 1 to 4 or 21 to 23, or a process according to any one of statements 5 to 23, wherein
[0156] Statement 25 R 21 , R 22 , R 23 , and R 24 are independently hydrogen or any C1-C 30 A catalyst system according to any one of statements 1 to 4 or 21 to 23, or a process according to any one of statements 5 to 23, wherein the R is a hydrocarbyl group.
[0157] Statement 26 R 4 and R 5 However, independently, C1~C 15 Alkyl groups, C4-C 20 Cycloalkyl groups, C4-C 20 Substituted cycloalkyl groups, C6-C 20 Aryl group, or C6-C 20A catalyst system according to any one of statements 1 to 4 or 21 to 25, or a process according to any one of statements 5 to 25, wherein the aryl group is a substituted aryl group.
[0158] Statement 27 R 4 and R 5 are independently a C1 to C5 alkyl group, a C4 to C 10 Cycloalkyl group, phenyl group, or C6-C 10 A catalyst system according to any one of statements 1 to 4 or 21 to 25, or a process according to any one of statements 5 to 25, wherein R is an aryl group.
[0159] Statement 28 R 4 and R 5 L, which together form a ring or ring system containing a phosphorus atom 45 It forms L 45 C1~C 20 A catalyst system according to any one of statements 1 to 4 or 21 to 25, or a process according to any one of statements 5 to 25, wherein the aryl group is a hydrocarbylene group.
[0160] Statement 29 The catalyst system of any one of statements 1-4 or 21-28, or the process of any one of statements 5-28, wherein each X is independently a halide, a carboxylate, or a β-diketonate.
[0161] Statement 30 The catalyst system of any one of statements 1 to 4 or 21 to 28, or the process of any one of statements 5 to 28, wherein the chromium salt is a chromium(III) carboxylate, a chromium(III) β-diketonate, or a chromium(III) halide.
[0162] Statement 31 The catalyst system according to any one of statements 1 to 4 or 21 to 28, or the process according to any one of statements 5 to 28, wherein the chromium salt is chromium(III) chloride or chromium(III) acetylacetonate.
[0163] Statement 32 The bicyclic 2-[(phosphinyl)aminyl]cyclic imine has the structure BPACI1, BPACI2, BPACI3, or BPACI4 [ka] and the bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex has the structure BPACICr1, BPACICr2, BPACICr3, or BPACICr4. [ka] A catalyst system according to any one of statements 1 to 4 or 28 to 31, or a process according to any one of statements 5 to 21 or 28 to 31, comprising:
[0164] All publications and patents mentioned herein are incorporated by reference in their entirety into this disclosure. The publications and patents mentioned herein may be used, for example, for the purpose of describing and disclosing constructs and methodologies described therein that may be used in conjunction with the subject matter described herein. Publications discussed throughout the text are provided solely for their disclosure prior to the filing date of this application. Nothing herein should be construed as an admission that the inventors are not entitled to antedate such disclosure by reason of prior work (including, but not limited to, experimental results).
[0165] Thus, the present disclosure is well adapted to achieve the ends and advantages mentioned, as well as those inherent therein. The detailed description is now complete. The particular embodiments disclosed above are merely illustrative, as the subject matter of the present disclosure may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Moreover, no limitations are intended to the details of construction or design shown herein, other than as described in the claims that follow. It is therefore apparent that the particular embodiments disclosed above may be altered or modified, and all such variations are deemed to be within the scope and spirit of the subject matter of the present disclosure. The protection sought herein is therefore as set forth in the claims herein.
Claims
1. i) (a) Structure BPACICr I or Structure BPACICr II [Case 1] or a bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex having the formula (b) a chromium salt and a compound of the structure BPACI I or the structure BPACI II [Case 2] A bicyclic 2-[(phosphinyl)aminyl]cyclic imine having the formula During the ceremony, R 21 , R 22 , R 23 , and R 24 are independently hydrogen or C 1 ~C 30 is an organyl group, L 1 , L 2 , and L 3 But independently, C 1 ~C 30 is a hydrocarbylene group, R 4 and R 5 But independently, C 1 ~C 30 is an organyl group, R 4 and R 5 optionally taken together to form a ring or ring system containing a phosphorus atom; 45 It forms L 45 C 1 ~C 30 is an organylene group, CrX p is a chromium salt, X is a monoanion, and p is an integer from 2 to 6, or the chromium salt and the bicyclic 2-[(phosphinyl)aminyl]cyclic imine, ii) an organoaluminum compound; and A catalyst system comprising:
2. 2. The catalyst system of claim 1, wherein the chromium salt is a chromium(III) carboxylate, a chromium(III) β-diketonate, or a chromium(III) halide.
3. 2. The catalyst system of claim 1, wherein the chromium salt is chromium(III) chloride or chromium(III) acetylacetonate.
4. 2. The catalyst system of claim 1, wherein the organoaluminum compound comprises an aluminoxane.
5. 5. The catalyst system of claim 4, wherein the aluminoxane comprises methylaluminoxane (MAO), modified methylaluminoxane, ethylaluminoxane, n-propylaluminoxane, isopropylaluminoxane, n-butylaluminoxane, sec-butylaluminoxane, iso-butylaluminoxane, t-butylaluminoxane, 1-pentylaluminoxane, 2-pentylaluminoxane, 3-pentylaluminoxane, isopentylaluminoxane, neopentylaluminoxane, or mixtures thereof.
6. 2. The catalyst system of claim 1, wherein the catalyst system has a molar ratio of aluminum from the organoaluminum compound to chromium from the chromium salt or chromium from the 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex in the range of 10:1 to 5,000:
1.
7. L 1 , L 2 , and L 3 2. The catalyst system of claim 1, wherein is independently a methylene group, an eth-1,2-ylene group, or a prop-1,3-ylene group.
8. R 21 , R 22 , R 23 , and R 24 are independently hydrogen or C 1 ~C 10 2. The catalyst system of claim 1, wherein the moiety is a hydrocarbyl group.
9. R 21 , R 22 , R 23 , and R 24 are independently hydrogen or C 1 ~C 10 is a hydrocarbyl group, L 1 , L 2 , and L 3 are independently a methylene group, an eth-1,2-ylene group, or a prop-1,3-ylene group; R 4 and R 5 But independently, C 1 ~C 10 is a hydrocarbyl group, R 4 and R 5 optionally taken together to form a ring or ring system containing a phosphorus atom; 45 It forms L 45 C 1 ~C 10 is a hydrocarbyl group, X is a monoanion; 9. The catalyst system of claim 8, wherein p is 3.
10. The bicyclic 2-[(phosphinyl)aminyl]cyclic imine has the structure BPACI1, BPACI2, BPACI3, or BPACI4 [C3] and said bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex has the structure BPACICr1, BPACICr2, BPACICr3, or BPACICr4. [C4] 2. The catalyst system of claim 1, having
11. a) i) ethylene; ii) (a) (i) Structure BPACICr I or Structure BPACICr II [C5] or a bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex having the formula (ii) a chromium salt and a compound of the structure BPACI I or the structure BPACI II [C6] A bicyclic 2-[(phosphinyl)aminyl]cyclic imine having the formula During the ceremony, R 21 , R 22 , R 23 , and R 24 are independently hydrogen or C 1 ~C 30 is an organyl group, L 1 , L 2 , and L 3 But independently, C 1 ~C 30 is a hydrocarbylene group, R 4 and R 5 But independently, C 1 ~C 30 is an organyl group, R 4 and R 5 optionally taken together to form a ring or ring system containing a phosphorus atom; 45 It forms L 45 C 1 ~C 30 is an organylene group, CrX p is a chromium salt, X is a monoanion, and p is an integer from 2 to 6, or the chromium salt and the bicyclic 2-[(phosphinyl)aminyl]cyclic imine, (b) an organoaluminum compound; and A catalyst system comprising: iii) optionally an organic reaction medium; and contacting the b) forming an oligomeric product in a reaction zone; A process including.
12. 12. The process of claim 11, wherein the chromium salt is a chromium(III) carboxylate, a chromium(III) β-diketonate, or a chromium(III) halide.
13. 12. The catalyst system of claim 11, wherein the chromium salt is chromium(III) chloride or chromium(III) acetylacetonate.
14. 12. The process of claim 11, wherein the organoaluminum compound comprises an aluminoxane comprising methylaluminoxane (MAO), modified methylaluminoxane, ethylaluminoxane, n-propylaluminoxane, isopropylaluminoxane, n-butylaluminoxane, sec-butylaluminoxane, iso-butylaluminoxane, t-butylaluminoxane, 1-pentylaluminoxane, 2-pentylaluminoxane, 3-pentylaluminoxane, isopentylaluminoxane, neopentylaluminoxane, or mixtures thereof.
15. 12. The process of claim 11, wherein the reaction zone has a molar ratio of aluminum from the organoaluminum compound to chromium from the chromium salt or 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex in the range of 10:1 to 5,000:
1.
16. R 21 , R 22 , R 23 , and R 24 are independently hydrogen or C 1 ~C 10 is a hydrocarbyl group, L 1 , L 2 , and L 3 are independently a methylene group, an eth-1,2-ylene group, or a prop-1,3-ylene group; R 4 and R 5 But independently, C 1 ~C 10 is a hydrocarbyl group, R 4 and R 5 optionally taken together to form a ring or ring system containing a phosphorus atom; 45 It forms L 45 C 1 ~C 10 is a hydrocarbyl group, X is a monoanion; 12. The process of claim 11 , wherein p is 3.
17. The bicyclic 2-[(phosphinyl)aminyl]cyclic imine has the structure BPACI1, BPACI2, BPACI3, or BPACI4 [C7] and said bicyclic 2-[(phosphinyl)aminyl]cyclic imine chromium salt complex has the structure BPACICr1, BPACICr2, BPACICr3, or BPACICr4. [C8] 12. The process of claim 11, comprising:
18. 12. The process of claim 11, wherein the ethylene trimer has a 1-hexene content of at least 95 wt.% and / or the ethylene tetramer has a 1-octene content of at least 95 wt.%.
19. The oligomer product has a C ratio of at least 0.5:1 8 / C 6 The process of claim 11 having a ratio.
Citation Information
Patent Citations
Ethylene Oligomerization Process
JP2020504751A
Catalyst Systems and Ethylene Oligomerization Method
US20170349505A1
Catalyst Systems and Ethylene Oligomerization Method
US20190169086A1
